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ABSTRACT 
Neurotrophic factors (NTFs) are secreted proteins which promote the survival of neurons, 
formation and maintenance of neuronal contacts, and regulate synaptic plasticity. NTFs 
are also potential drug candidates for the treatment of neurodegenerative diseases. 
Parkinson’s disease (PD) is mainly caused by the degeneration of midbrain dopaminergic 
(mDA) neurons. Current therapies for PD do not stop the neurodegeneration or repair the 
affected neurons. Thus, search of novel neurotrophic factors for midbrain dopaminergic 
neurons, which could also be used as therapeutic proteins, is highly warranted. 
In the present study, we identified and characterized a novel protein named 
conserved dopamine neurotrophic factor (CDNF), a homologous protein to 
mesencephalic astrocyte-derived neurotrophic factor (MANF). Others have shown that 
MANF supports the survival of embryonic midbrain dopaminergic neurons in vitro, and 
protects cultured cells against endoplasmic reticulum (ER) stress. CDNF and MANF 
form a novel evolutionary conserved protein family with characteristic eight conserved 
cysteine residues in their primary structure. The vertebrates have CDNF and MANF 
encoding genes, whereas the invertebrates, including Drosophila and Caenorhabditis 
have a single homologous CDNF/MANF gene. 
In this study we show that CDNF and MANF are secreted proteins. They are widely 
expressed in the mammalian brain, including the midbrain and striatum, and in several 
non-neuronal tissues. We expressed and purifi ed recombinant human CDNF and MANF 
proteins, and tested the neurotrophic activity of CDNF on midbrain dopaminergic 
neurons using a 6-hydroxydopamine (6-OHDA) rat model of PD. In this model, a single 
intrastriatal injection of CDNF protected midbrain dopaminergic neurons and striatal 
dopaminergic fi bers from the 6-OHDA toxicity. Importantly, an intrastriatal injection 
of CDNF also restored the functional activity of the nigrostriatal dopaminergic system 
when given after the striatal 6-OHDA lesion. Thus, our study shows that CDNF is a 
potential novel therapeutic protein for the treatment of PD.
In order to elucidate the molecular mechanisms of CDNF and MANF activity, we 
resolved their crystal structure. CDNF and MANF proteins have two domains; an amino 
(N)-terminal saposin-like domain and a presumably unfolded carboxy (C)-terminal 
domain. The saposin-like domain, which is formed by fi ve α-helices and stabilized by 
three intradomain disulphide bridges, may bind to lipids or membranes. The C-terminal 
domain contains an internal cysteine bridge in a CXXC motif similar to that of thiol/
disulphide oxidoreductases and isomerases, and may thus facilitate protein folding in 
the ER. 
Our studies suggest that CDNF and MANF are novel potential therapeutic 
proteins for the treatment of neurodegenerative diseases. Future studies will reveal the 
neurotrophic and cytoprotective mechanisms of CDNF and MANF in more detail. 
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1.1. Neurotrophic factors: The concept 
Correct formation of neuronal contacts 
is essential for the development of 
vertebrate nervous system. Different 
cell-intrinsic and cell-extrinsic factors 
regulate this process, including intrinsic 
transcriptional programs, and extrinsic, 
secreted or cell-surface bound molecules 
provided by neighbouring cells, tissues 
and extracellular matrix. Neurotrophic 
factors are an important group of cell-
extrinsic, secreted proteins, which regulate 
the neuronal survival and death at the 
time of synapse formation with the target 
tissue or with other neurons. As the name 
implies, neurotrophic factors provide 
“nourishment” for postmitotic neurons 
which they need for the survival.
During embryogenesis neurons are 
produced in excess. The overproduced 
neurons are removed during the 
developmental period of programmed 
cell death (PCD), which is to ensure 
that the target tissue receives optimal 
number of neuronal contacts. It has been 
estimated that 20-80% of neurons in 
a given population die by apoptosis, a 
cell-intrinsic default program of death 
(Oppenheim 1991). NTFs have a crucial 
role in preventing the apoptotic death 
and in regulating the number of target-
innervating neurons. The concept of 
neurotrophic factors is largely based on the 
studies on nerve growth factor (NGF), the 
fi rst growth factor and neurotrophic factor 
identifi ed in the 1950’s (Levi-Montalcini 
1987). According to the original 
neurotrophic factor hypothesis, the target 
tissue secretes NTFs in limited amounts, 
which leads to neuronal competition of the 
trophic support. As a result, only neurons 
receiving a sufficient trophic support 
survive and synapse with the target, 
whereas other neurons die apoptotically. 
The target-derived NTF binds to a receptor 
at axon terminals, the ligand-receptor 
complex is endocytosed and retrogradely 
transported into the cell soma, where 
survival promoting signal pathways are 
activated, and apoptotic death is inhibited. 
NGF functions as a target–derived factor 
for sensory and sympathetic neurons in the 
peripheral nervous system (PNS) (Huang 
and Reichardt 2001; Glebova and Ginty 
2005). The neurotrophic factor concept 
is well-established in the development of 
the PNS; however, the role of NTFs in 
the development and maintenance of the 
central nervous system (CNS) is less clear, 
although intensively studied.  
The classification of “neurotrophic 
factor” includes a wide range of proteins 
with different functional specificities. 
Traditionally, neurotrophic factors 
consist of three main protein families: 
Neurotrophins (Lu et al. 2005; Huang and 
Reichardt 2001), glial cell line-derived 
neurotrophic factor (GDNF) family 
ligands (GFLs) (Airaksinen and Saarma 
2002; Bespalov and Saarma 2007), and 
neuropoietic cytokines (also referred as 
interleukin-6 (IL-6) family) (Bauer et 
al. 2007; Heinrich et al. 2003). All these 
factors signal via transmembrane receptor 
tyrosine kinases, or have receptors 
associated with kinases (Bespalov and 
Saarma 2007). In addition to these three 
families, various other growth factors also 
have neurotrophic activities. Examples of 
these include the members of transforming 
growth factor β  (TGFβ), vascular 
endothelial growth factor (VEGF), insulin-
like growth factor (IGF) and fibroblast 
growth factor (FGF) families (Zacchigna 
et al. 2008; Grothe and Timmer 2007).
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Different NTFs affect on specific 
sets of neuronal subpopulations, which 
are genetically competent to respond, i.e. 
express cognate receptors on their surface, 
and have appropriate transcriptional 
programs. In addition to the survival 
promoting activity, NTFs affect on 
neuronal migration, differentiation and 
maturation. They regulate neuritogenesis, 
formation and maintenance of synaptic 
contacts, and synaptic plasticity. They 
also promote the regeneration of neurons 
after injury (Airaksinen and Saarma 
2002; Huang and Reichardt 2001). It is 
well established that neurons may receive 
neurotrophic support from various sources; 
not only from the the target (Fig. 1) (Davies 
2003; Krieglstein 2004). Neurotrophic 
factors also affect on non-neuronal cells 
and tissues, and have important roles, for 
example, in angiogenesis (Zacchigna et al. 
2008).
Evidence suggests that  NTFs 
function also in the development of 
invertebrate nervous system. In the fly 
Drosophila, glial-derived neurotrophic 
support has been reported (Booth et al. 
2000). As in the vertebrates, fl y neurons 
are originally overproduced, and the 
excess of neurons is removed by PCD 
during development (White et al. 1994). 
However, the identification of NTFs in 
arthropods and nematodes was for long 
unsuccessful (Jaaro et al. 2001; Bothwell 
2006). Only recently Zhu and colleagues 
(Zhu et al. 2008) described Drosophila 
Neurotrophin 1 (DNT1; spätzle 2) part 
of which is structurally homologous to 
all known neurotrophins. Furthermore, 
the fi rst ligand-receptor pair homologous 
to neurotrophins and Trk receptors has 
been described in the mollusc Aplysia 
snail (Kassabov 2008). Although GFL 
homologs have not been found in insect 
genomes (Airaksinen et al. 2006), an 
orphan homolog for GDNF receptor RET 
(rearranged during transfection) is present 
in Drosophila (Sugaya et al. 1994). Several 
Review of the literature
Figure 1. Neurons may receive NTFs from different sources, including the target (A); 
intermediate target cells or glial cells (B); or presynaptic neurons (C). D) Autocrine trophic 
support. E) Neurons without a suffi cient trophic support die by apoptosis. 
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insect genomes also contain a GDNF 
family receptor (GFR)-like gene, which is 
found in C. elegans as well (Airaksinen et 
al. 2006). Thus, NTFs seem necessary not 
only for the development and maintenance 
of the “complex” vertebrate nervous 
system with high number of neurons, but 
also for the more “simple” nervous system 
of invertebrates. 
1.2. Neurotrophic factors for midbrain 
dopaminergic neurons
In this work our interest has been on 
neurotrophic factors supporting the 
survival of dopaminergic neurons located 
in the substantia nigra (SN) in the midbrain. 
These neurons form the major neuronal 
population degenerating in Parkinson’s 
disease, a progressive neurodegenerative 
movement disorder. The role of target-
derived NTFs in the development of 
midbrain dopaminergic neurons has 
remained unclear (Andressoo and Saarma 
2008). Potential target-derived factors for 
these neurons include GDNF, neurturin 
(NRTN), brain-derived neurotrophic 
factor (BDNF), neurotrophin-4 (NT-4) and 
FGF-2 (Krieglstein 2004). 
1.2.1. Neurotrophins
The family of neurotrophins include 
four members in mammals: NGF, BDNF 
(Barde et al. 1982; Leibrock et al. 1989), 
neurotrophin-3 (NT-3) (Ernfors et al. 
1990; Hohn et al. 1990; Maisonpierre 
et al. 1990; Rosenthal et al. 1990) and 
NT-4 (Berkemeier et al. 1991; Hallböök 
et al. 1991). Neurotrophins signal via 
two transmembrane receptor systems; 
tropomyosin-related kinase (Trk) receptor 
or p75 neurotrophin receptor (p75NTR), 
a member of tumour necrosis factor 
(TNF) receptor family (Chao et al. 2006). 
Ligand binding is selective to the different 
Trk receptors (TrkA, B, C), whereas all 
neurotrophins bind to p75NTR. NGF binds 
specifically to TrkA, BDNF and NT-4 
bind to TrkB, and NT-3 binds to TrkC. 
Signalling mediated by Trk receptor 
preferentially promotes the cell survival, 
whereas signalling mediated by p75NTR can 
either facilitate Trk-mediated survival or, 
in the absence of Trk receptors, mediate 
apoptotic cell death (Roux and Barker 
2002).
Structurally neurotrophins are 
classified to the cystine-knot cytokines 
(Structural Classification of Proteins; 
SCOP) (Murzin et al. 1995), and 
they function as homodimers. They 
are synthetized as precursors, pro-
neurotrophins of 30-35 kDa. The pro-
part is proteolytically cleaved resulting 
to a mature protein of 12-13 kDa (Lu et 
al. 2005). Both the pro- and mature forms 
of neurotrophins are active in signalling, 
although their biological effects can 
be opposite:  proNGF and proBDNF 
signalling via p75NTR mediates apoptotic 
cell death whereas mature NGF and BDNF 
bind to Trk receptors and promote cell 
survival (Chao et al. 2006; Lee and Chao 
2001; Lu et al. 2005). Thus, the biological 
activity of neurotrophins can be regulated 
by the cleavage of  pro-region (Chao and 
Bothwell 2002). 
Neurotrophins support various 
neuronal populations in the PNS and 
CNS (Huang and Reichardt 2001). As 
mentioned earlier, NGF promotes the 
survival of sympathetic and sensory 
neurons in the PNS. It also promotes the 
survival of cholinergic neurons in the basal 
forebrain, which presumably participate 
in memory functions that are affected in 
Alzheimer’s disease (AD) (Chao et al. 
2006). In adult, NGF has an essential role 
in pain mechanisms (Hefti et al. 2006). 
Review of the literature
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BDNF promotes the survival of peripheral 
sensory neurons (Huang and Reichardt 
2001), and modulates synaptic plasticity 
of various brain neurons (Arancio and 
Chao 2007). Outside the nervous system, 
BDNF has a role in vascular development 
and angiogenesis after injury (Kermani 
and Hempstead 2007). NT-3 promotes 
the survival of sympathetic and sensory 
neurons and promotes the growth of 
sympathetic axons towards their targets 
(Glebova and Ginty 2005; Huang and 
Reichardt 2001). 
BDNF was the fi rst NTF described to 
promote the survival and dopamine uptake 
of embryonic midbrain dopaminergic 
neurons in vitro (Hyman et al. 1991; 
Knusel et al. 1991). Also NT-3 and 
NT-4 promote the survival of embryonic 
midbrain dopaminergic neurons in culture 
(Hyman et al. 1994; Hynes et al. 1994). 
BDNF and its receptor TrkB are expressed 
in the dopaminergic neurons in the SN 
(Numan and Seroogy 1999; Venero et 
al. 2000), and BDNF mRNA has been 
detected in the striatum, although at low 
level (Hofer et al. 1990). BDNF can be 
retrogradely transported by dopaminergic 
neurons from the striatum to SN (Mufson 
et al. 1994), which suggests a role for 
BDNF as a target-derived factor for nigral 
dopaminergic neurons. However, gene 
ablation studies in mice have not revealed 
an essential role for endogenous BDNF 
or TrkB on the survival and maturation 
of midbrain dopaminergic system. BDNF 
deficient mice, which die at age of ~21 
days, do not have signifi cant alterations 
in the nigrostriatal dopaminergic system 
(Conover et al. 1995; Ernfors et al. 
1994; Jones et al. 1994). However, 
Baker and colleagues (Baker et al. 2005) 
reported that the number of dopaminergic 
dendrites was reduced postnatally in the 
SN of BDNF-deficient mice, although 
the number of dopaminergic neurons 
in the SN was not affected, suggesting 
that BDNF has a role in the phenotypic 
maturation of dopaminergic neurons. 
Conditional removal TrkB from the 
dopaminergic system in embryo did not 
affect the numbers of nigral dopaminergic 
neurons even at 2 years of age (Kramer 
et al. 2007), indicating a minor role for 
TrkB signalling in target innervation or 
maintenance of dopaminergic neurons in 
the SN. Differently from this, conditional 
removal of BDNF expression from the 
developing midbrain-hindbrain (MHB) 
region in embryonic mice resulted in early 
postnatal reduction of a subpopulation 
of tyrosine hydroxylase (TH)-positive 
dopaminergic neurons in the SN, although 
the total number of nigral neurons was not 
signifi cantly reduced (Baquet et al. 2005), 
suggesting that BDNF is required for the 
differentiation of dopaminergic phenotype. 
Although it now seems clear that BDNF 
is not an essential survival factor for 
midbrain dopaminergic neurons in vivo, 
its role in the dopaminergic system is not 
fully understood; thus, further studies with 
conditional mouse models are needed. 
1.2.2. GDNF family ligands 
GDNF is a potent neurotrophic factor 
for midbrain dopaminergic neurons. It 
was originally isolated from the culture 
medium of a rat B49 glial cell line based 
on its ability to promote dopamine uptake, 
survival and morphological differentiation 
of embryonic midbrain dopaminergic 
neurons in culture (Lin et al. 1993). 
Other members of GFLs include NRTN 
(Kotzbauer et al. 1996), artemin (ARTN) 
(Baloh et al. 1998) and persephin (PSPN) 
(Milbrandt et al. 1998). The homology 
of GFL amino acid sequences is 40-50% 
(Saarma 2000). 
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Structurally GFLs are related to 
TGFβ protein superfamily which belongs 
to cystine-knot cytokines (Murzin et al. 
1995). Although the overall amino acid 
sequence homology between GDNF and 
the members of TGFβ superfamily is less 
than 20%, seven cysteine residues are 
conserved in their primary structure and 
determine the protein fold (Lin et al. 1993). 
The cysteines form three intramolecular 
and one intermolecular disulphide bonds 
(Eigenbrot and Gerber 1997; Ibáñez 1998). 
Similarly to neurotrophins, all members of 
the TGFβ family are functional as dimers 
(Sun and Davies 1995; Vitt et al. 2001). 
GDNF family ligands are synthesized 
as prepro-proteins, from which the signal 
peptide (pre) is cleaved upon secretion 
(Fig. 2A). An enzymatic cleavage of 
the proGFL results in an active, mature 
protein, which is functional as a disulfi de-
bonded homodimer (Fig. 2B). Mature 
GDNF consists of 134 amino acids and 
contains two N (asparagine)-linked 
glycosylation sites. The molecular mass 
of an unglycosylated GDNF monomer is 
16 kDa (Lin et al. 1993; Lin et al. 1994). 
GDNF, NRTN and ARTN are basic 
proteins which bind extracellular matrix 
heparan-sulphate proteoglycans; thus, their 
diffusion is limited in tissue (Airaksinen 
and Saarma 2002). The extracellular 
matrix may also serve as a depot for 
storage and slow release of GDNF (Lin et 
al. 1994) and other GFLs.  
GFLs signal using transmembrane 
receptor tyrosine kinase RET and glycosyl-
phosphatidylinositol (GPI) linked GDNF 
family alpha (GFRα) coreceptors, which 
determine the ligand specificity (Fig. 
2C). Dimeric GFL binds fi rst to a GFRα 
coreceptor on the cell membrane, and the 
complex induces subsequent dimerization 
and tyrosine phosphorylation of RET. 
Figure 2. A) Schematic presentation of 
the primary structure of prepro-GDNF and 
mature GDNF. Seven conserved cyteines (*) 
and two glycosylation sites (Y) of mature 
GDNF are indicated. According to Saarma 
and Sariola (1999). B) GDNF homodimer 
(Eigenbrot and Gerber 1997). Finger-regions 
are formed by antiparallel β-strands connected 
by loop regions. C) GFL receptor system. 
Dimeric GFL binds to coreceptor GFRα, the 
GFL-GFRα complex dimerizes and activates 
RET. Phosphorylation (P) of tyrosine kinase 
domain (TK) of RET leads to the activation 
of intracellular signalling cascades. Preferred 
ligand-coreceptor pairs are indicated. 
According to Airaksinen and Saarma (2002).
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This leads to the activation of intracellular 
signalling cascades (Airaksinen and 
Saarma 2002; Santoro et al. 2004) which 
induce subsequent changes in gene 
expression, protein synthesis and cellular 
response. Four coreceptors (GFRα1-4) 
have been identifi ed, and each GFL binds 
preferentially one of them: GFRα1 is the 
main co-receptor for GDNF; GFRα2 for 
NRTN; GFRα3 for ARTN, and GRFα4 
for PSPN, respectively (Airaksinen and 
Saarma 2002; Bespalov and Saarma 
2007). The crystal structure of GDNF 
dimer bound to GFRα1, and ARTN in 
a complex with GFRα3 coreceptor has 
been recently determined (Parkash et al. 
2008; Wang et al. 2006). An alternative 
receptor for GFLs, in addition to RET, is 
a neural cell adhesion molecule (NCAM) 
(Paratcha et al. 2003). RET receptor was 
originally identifi ed as an oncogene, and 
activating mutations of RET are related 
to the development of cancer (Santoro et 
al. 2004). Inactivating mutations of RET 
induce the development of Hirschsprung 
disease characterized by aganglionic 
megacolon (Santoro et al. 2004). 
In addition to the effects on midbrain 
dopaminergic neurons, GDNF affects 
several neuronal populations in the 
CNS and PNS (Airaksinen and Saarma 
2002). GDNF promotes the survival of 
noradrenergic neurons in locus coeruleus 
(LC) (Arenas et al. 1995), and seems 
crucial for their maintenance in adult 
(Pascual et al. 2008). GDNF also promotes 
the survival of motoneurons (Henderson et 
al. 1994; Oppenheim et al. 1995), sensory 
(Henderson et al. 1994; Oppenheim et al. 
1995; Yan et al. 1995), sympathetic (Trupp 
et al. 1995; Coulpier and Ibáñez 2004), 
and parasympathetic neurons (Buj-Bello 
et al. 1995; Hashino et al. 2001). GDNF 
has also important functions outside the 
nervous system. GDNF signalling is 
essential for migration and proliferation 
of enteric neuronal precursors (Cacalano 
et al. 1998; Enomoto et al. 1998; Moore 
et al. 1996; Pichel et al. 1996; Sanchez et 
al. 1996), and for kidney morphogenesis, 
as GDNF knockout mice have severe 
renal agenesis at the time of birth (Moore 
et al. 1996; Pichel et al. 1996; Sanchez 
et al. 1996). GDNF is also important for 
spermatogonial renewal and differentiation 
(Meng et al. 2001).
Similarly with GDNF, NRTN is 
a potent survival factor for midbrain 
dopaminergic neurons in vitro and in vivo 
(Horger et al. 1998). It has protective 
and restorative effects on mDA neurons 
in animal models of PD which are 
comparable to those of GDNF. For 
example, intrastriatal NRTN given after 
striatal 6-OHDA lesion showed protective 
effects on mDA neurons (Rosenblad 
et al. 1999), and NRTN-secreting 
intranigral grafts protected against medial 
forebrain bundle (MFB) lesion induced 
by 6-OHDA (Åkerud et al. 1999) in rats. 
NRTN expressing adeno-associated virus 
serotype 2 (AAV2; CERE-120) induced 
functional recovery and preservation of 
mDA neurons in 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP)-treated 
monkeys (Kordower et al. 2006; Herzog et 
al. 2007), and has been tested in clinical 
trials (see 1.4.5). PSPN also promotes 
the survival of mDA neurons in vitro 
(Milbrandt et al. 1998). In vivo, intranigral 
PSPN protected against intrastriatal 
6-OHDA lesion in rats (Milbrandt et al. 
1998), and PSPN expressing intrastriatal 
grafts protected against striatal 6-OHDA 
lesion in mice (Åkerud et al. 2002). It is 
likely that NRTN and PSPN signalling 
in mDA neurons is mediated by 
GFRα1 instead of GFRα2 and GFRα4, 
respectively, since mDA neurons derived 
from GFRα1 knockout mouse embryos do 
Review of the literature
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not respond to NRTN in vitro (Cacalano et 
al. 1998) and most of the Gfra4 transcripts 
expressed in the central nervous system 
are not functional (Lindahl et al. 2000; 
Lindfors et al. 2006).
1.2.3. Effects of GDNF on midbrain 
dopaminergic neurons
Since GDNF was originally discovered as 
a trophic factor for midbrain dopaminergic 
neurons, its function on the midbrain 
dopaminergic system in vivo has been 
extensively studied. The administration 
of exogenous GDNF protein into adult 
rodent brain clearly affects the midbrain 
dopaminergic system by increasing 
locomotor activity (Hebert et al. 1996; 
Hoane et al. 1999; Hudson et al. 1995), TH 
expression (Hoffer et al. 1994; Hudson et 
al. 1995), dopamine levels and dopamine 
metabolism (Lapchak et al. 1997), and 
by inducing sprouting of dopaminergic 
neurons (Hudson et al. 1995). Negative 
effects related to the administration of 
exogenous GDNF have also been reported 
in rats, including decrease in the food 
consumption (Hudson et al. 1995), loss 
of body weight and allodynia (pain) 
(Hoane et al. 1999). Downregulation of 
TH expression and aberrant sprouting 
of dopaminergic fibers were seen after 
sustained lentiviral expression of GDNF 
in the striatum (Georgievska et al. 2002).
Whether GDNF is a target-derived 
neurotrophic factor for midbrain 
dopaminergic neurons is not clear 
(Andressoo and Saarma 2008; Krieglstein 
2004). PCD of midbrain dopaminergic 
neurons occurs postnatally in two phases, 
peaking at the postnatal day 2 (P2) and 
P14 (Oo and Burke 1997). GDNF mRNA 
is expressed at higher levels in the early 
postnatal striatum as compared to that of 
adult (Choi-Lundberg and Bohn 1995; 
Schaar et al. 1993; Strömberg et al. 1993), 
which supports the potential role of GDNF 
as a target derived NTF. RET and GFRα1 
are also expressed in the SN, where the 
dopaminergic cell bodies are located 
(Choi-Lundberg and Bohn 1995; Golden 
et al. 1998; Trupp et al. 1997; Widenfalk 
et al. 1997). Furthermore, intrastriatally 
injected GDNF is transported retrogradely 
from the adult rat striatum to SN (Tomac 
et al. 1995b), in consistent with the role of 
GDNF as a target-derived NTF.
GDNF knockout mice die at birth 
(Airaksinen and Saarma 2002); thus, 
only the prenatal development of these 
mice can be studied. At the time of birth, 
the survival of dopaminergic neurons in 
the SN and noradrenergic neurons in the 
LC is not affected in the GDNF defi cient 
mice (Cacalano et al. 1998; Enomoto 
et al. 1998; Moore et al. 1996; Pichel et 
al. 1996; Treanor et al. 1996). Similarly 
with the GDNF deficient mice, RET or 
GFRα1 knockout mice, which also die 
at birth, do not have alterations in nigral 
dopaminergic neurons as compared to the 
wild type (Airaksinen and Saarma 2002). 
GDNF heterozygous mice are viable and 
fertile (Granholm et al. 2000). When aged, 
they show decline in motor performance 
and TH expression in nigral dopaminergic 
neurons, suggesting that GDNF has a 
role in the maintenance of midbrain 
dopaminergic system (Boger et al. 2006). 
Recent studies with conditional mouse 
models of GDNF (Pascual et al. 2008) and 
RET (Kramer et al. 2007) indicate that 
GDNF is necessary for the maintenance 
of adult mouse dopaminergic neurons. 
When GDNF expression was suppressed 
ubiquitously in adult mice, a signifi cant 
reduction in the number of dopaminergic 
neurons in the SN and ventral tegmental 
area (VTA) was observed at seven months 
later, and the noradrenergic neurons of LC 
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were almost absent (Pascual et al. 2008). 
The mice also showed a progressive 
hypokinetic syndrome. These results 
suggest that continuous supply of GDNF 
is essential for the survival of adult 
cathecolaminergic neurons (Pascual et al. 
2008). In contrast, conditional embryonic 
inactivation of Ret in cathecolaminergic 
neurons did not cause signifi cant defects 
in midbrain dopaminergic neurons in mice 
less than one year of age, as analyzed 
by two research groups (Jain et al. 2006, 
Kramer et al. 2007), suggesting that RET 
signalling is not crucial for the survival of 
mDA neurons during the early postnatal 
PCD periods. However, conditional 
removal of Ret caused progressive loss of 
nigral dopaminergic neurons in adult mice 
starting around one year of age, which 
was accompanied with the degeneration 
of striatal nerve terminals. In addition, 
significant gliosis and inflammation 
were deteced in the striatum and SN, 
respectively, in the aged mice (Kramer et 
al. 2007). Differently from the conditional 
ablation of GDNF in adult (Pascual et 
al. 2008), conditional inactivation of 
Ret did not cause marked defects in the 
dopaminergic neurons of the VTA or in 
the noradrenergic neurons of LC (Kramer 
et al. 2007). The milder phenotype of 
RET defi cient mice (Kramer et al. 2007) 
as compared to the GDNF defi cient mice 
(Pascual et al. 2008) suggests that the 
survival promoting signals of GDNF on 
dopaminergic neurons and noradrenergic 
neurons are mediated not only by RET but 
also by another receptor. An alternative 
possibility that could explain the 
differences between the above phenotypes 
is that the lack of RET signalling in 
embryonic dopaminergic neurons 
is compensated with other survival 
promoting signals independent of GDNF 
and RET. The difference may also be due 
to the different genetic background of the 
mice used. Finally, it is not completely 
excluded that the phenotype loss of GDNF 
deficient mice (Pascual et al. 2008) is 
unspecifi c due to high concentrations of 
tamoxifen used. It would be important 
to create comparable animal models for 
the current conditional GDNF and RET 
models (i.e. conditionally inactivate Gdnf 
in embryonic cathecolaminergic neurons, 
and ubiquitously inactivate Ret in adult 
mice) in order to clarify the signifi cance of 
GDNF-RET signalling in the development 
and maintenance of midbrain dopaminergic 
system. 
1.2.4. Other trophic factors for midbrain 
dopaminergic neurons
In addition to the GFLs and neurotrophins, 
several growth and trophic factors 
have neurotrophic effects on midbrain 
dopaminergic neurons, including the 
members of TGFβ family, FGF-2 and 
cytokines (Table 1). Cytokines are a large 
group of pleiotropic molecules, which 
include interleukins, tumour necrosis 
factor (TNF) family and hematopoietic 
cytokines (e.g. erythropoietin; EPO). 
Neuropoietic cytokines, one of the three 
main groups of neurotrophic factors, 
affect both neurons and hematopoietic 
cells. They function in infl ammation and 
immune response, regulate neurogenesis 
and stem cell fate, and modulate synaptic 
plasticity and various behaviours (Bauer et 
al. 2007; Heinrich et al. 2003). Members 
of this group include interleukin-6 (IL-6), 
IL-11, leukaemia inhibitory factor (LIF), 
ciliary neurotrophic factor (CNTF), 
cardiotrophin-1 (CT-1), oncostatin M 
(OSM), cardiotrophin-like cytokine 
(CLC) and B cell stimulating factor 3 
(BSF3) (Heinrich et al. 2003). They have 
a characteristic four-helix bundle three-
Review of the literature
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dimensional structure, and they signal 
using glycoprotein (gp)130, LIF and OSM 
receptors. IL-6 and CNTF show trophic 
effects on midbrain dopaminergic neurons 
(Engele 1998; Hagg and Varon 1993) 
and CNTF on motoneurons in particular 
(Sendtner et al. 2000). 
Some of the survival factors, including 
FGF-2 and bone morphogenetic proteins 
(BMPs), affect midbrain dopaminergic 
neurons indirectly by stimulating glial cells 
which likely synthetize and release trophic 
factors thus promoting neuronal survival 
(Knusel et al. 1990; Jordan et al. 1997). 
Different trophic factors may also function 
in a co-operative manner. TGFβ potentiates 
the survival promoting effects of GDNF 
on midbrain dopaminergic neurons in vitro 
(Krieglstein et al. 1998). However, TGFβ2 
and GDNF double knockout mice dying at 
birth do not show defects in the midbrain 
dopaminergic system (Rahhal et al. 2009). 
Further studies are needed to elucidate the 
effects of different growth factors on the 
development and maintenance of midbrain 
dopaminergic neurons.
1.3. Midbrain dopaminergic system
Dopamine, a catecholamine, is a 
neurotransmitter of anatomically and 
functionally distinct neuronal groups in the 
CNS. The largest group of dopaminergic 
neurons is located in the ventral midbrain 
(mesencephalon) and is referred as 
midbrain (mesencephalic) dopaminergic 
neurons. These neurons form two major 
nuclei, the substantia nigra pars compacta 
(SNpc, A9) and ventral tegmental area 
(VTA, A10; Fig. 3A) (Prakash and Wurst 
2006). Cell bodies in the SNpc project 
axons into dorsal striatum (caudate nucleus 
and putamen) forming the nigrostriatal 
pathway, which is important in controlling 
voluntary movements. Degeneration of 
this pathway is the major cause of PD 
(Dauer and Przedborski 2003). Neurons 
in the VTA send projections to the limbic 
areas (nucleus accumbens, amygdala, and 
olfactory tubercle) and prefrontal cortex 
forming the mesolimbic and mesocortical 
pathways, respectively. These pathways 
participate in the regulation of emotion-
related behaviour such as motivation and 
reward. A third, smaller group of mDA 
neurons is located in the retrorubral fi eld 
(A8), and is functionally related to the A10 
group (Abeliovich and Hammond 2007; 
Prakash and Wurst 2006). Dysfunction of 
the dopaminergic limbic system is related 
to schizophrenia, depression and addiction 
(Van den Heuvel and Pasterkamp 2008). 
In humans, mDA cell groups consist of 
400.000-600.000 neurons, of which over 
70% is located in the SNpc. In rats, mDA 
neuronal groups consist of 40.000-45.000 
cells, half of which is located in the SNpc 
(Björklund and Dunnett 2007).
The postmitotic precursors of mDA 
neurons are born in the ventricular-
subventricular zone in the midbrain-
hindbrain region around embryonic day 
10.5 (E10.5) of mouse development (Fig. 
3B) (Prakash and Wurst 2006). They 
migrate from the ventricular zone along 
radial glia to the ventral midbrain where 
SNpc and VTA are subsequently formed 
(Smits et al. 2006). The dopaminergic 
fate is determined by interplay between 
extracellular inductive signals and 
transcriptional programs of the cell. FGF8 
secreted from the midbrain-hindbrain 
border (isthmus) and sonic hedgehog 
(SHH) secreted from the notochord 
are inductive signals which determine 
the permissive region where mDA 
progenitors are born (Smidt and Burbach 
2007). Extracellular signalling of TGFβ 
is essential for the induction, and Wnt 
signalling is important in establishing 
10



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































midbrain-hindbrain region (Smidt and 
Burbach 2007). During differentiation of 
the postmitotic mDA neuron precursors, 
the transcription factors expressed include 
nuclear orphan receptor Nr4a2 (Nurr1), 
engrailed 1 and 2 (En1/2), LIM homeobox 
transcription factor Lmx1b and paired-like 
homeodomain transcription factor 3 (Pitx3) 
(Abeliovich and Hammond 2007; Smits et 
al. 2006). Nurr1 regulates the expression of 
proteins required for dopamine synthesis 
and transport, including TH, vesicular 
monoamine transporter 2 (VMAT2) and 
dopamine transporter (DAT) (Burbach 
and Smidt 2006). TH is the rate-limiting 
enzyme of dopamine biosynthesis, 
and used commonly as a marker for 
dopaminergic neurons. Expression of 
TH is induced at E11.5 (Burbach and 
Smidt 2006). The fi rst mDA axons can be 
detected at E11 in mouse, and at E14.5 
many of them have reached their targets 
(Abeliovich and Hammond 2007). At E18 
striatal dopaminergic innervation is still 
partial, but completed by P4 in rodents 
(Burke 2004). Axon guidance molecules 
including ephrins, netrins and slits 
instruct the growth of dopaminergic axons 
Review of the literature
Figure 3. A) Schematic presentation of mesencephalic dopaminergic pathways in mouse brain. 
A9, substantia nigra; A10, ventral tegmental area. Am, amygdala; CTX prefrontal cortex; 
NA, nucleus accumbens; OT, olfactory tubercle. Figure modifi ed from “The Mouse Brain in 
Stereotaxic Coordinates” by George Paxinos and Keith B. Franklin (2nd edition), copyright by 
Academic Press (2001). B) Development of mDA neurons (Abeliovich and Hammond 2007; 
Prakash and Wurst 2006). GDNF is a potential target-derived factor for mDA neurons, which may 
counteract early postnatal PCD. GDNF maintains mDA system in adult (Pascual et al. 2008). 
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towards their targets (Van den Heuvel and 
Pasterkamp 2008). 
As described earlier, developing 
neuronal populations undergo a regulated 
natural cell death which determines the 
final neuronal number in adults. The 
purpose of this developmental cell death 
is to remove excess of neurons and 
adjust neuronal numbers with size of 
the target, and to eliminate neurons with 
incorrect target connections (Oppenheim 
1991). Whether the number of midbrain 
dopaminergic neurons is regulated by 
PCD during development is still uncertain. 
Burke and colleagues (Burke 2004; 
Jackson-Lewis et al. 2000; Oo and Burke 
1997) have shown that mDA neurons in 
the SN undergo developmental apoptotic 
cell death. According to these studies, 
a natural cell death in the SNpc occurs 
postnatally in rats and mice in a biphasic 
manner. The fi rst, major peak of death is 
readily after birth at P2, and the second, 
minor peak at P14 (Oo and Burke 1997; 
Jackson-Lewis et al. 2000). In contrast 
to these results, some evidence indicates 
that the number of mDA neurons is not 
regulated by apoptotic cell death in mice 
(Lieb et al. 1996). The rodent mDA system 
is mature around the third postnatal week 
(Prakash and Wurst 2006). 
1.4. Parkinson’s disease
PD is a gradually progressive neuro-
degenerative disorder, which affects 
about 1-2% of population over 50 years 
of age (Thomas and Beal 2007). The 
cardinal motor symptoms of PD and other 
parkinsonian sydromes include resting 
tremor, rigidity, slowness of voluntary 
movement (hypokinesia) and postural 
instability (Dauer and Przedborski 2003). 
The main cause of motor symptoms is the 
degeneration of dopaminergic neurons in 
the SNpc. These neurons project axons 
to the putamen and nucleus caudatus 
(collectively known as striatum) forming 
the nigrostriatal pathway, which is 
degenerated in the disease. However, the 
neurodegeneration in PD is not restricted 
to the SNpc. Non-motor symptoms of 
PD include anosmia (inability to perceive 
smells) and dysfunction of the autonomic 
nervous system. Characteristic pathology 
at cellular level is the accumulation of 
intracytoplasmic protein aggregates called 
Lewy bodies, which contain misfolded 
protein α-synuclein and other proteins, 
including ubiquitin, proteasome subunits, 
heat-shock proteins and neurofilaments 
(Lotharius and Brundin 2002). As 
clinical symptoms appear, the disease is 
already highly progressed: about 60% of 
the dopaminergic cells in the SNpc are 
degenerated, and dopamine levels in the 
putamen are reduced by ~80% (Dauer 
and Przedborski 2003). The dopaminergic 
neurons of VTA are much less affected 
than those of SNpc (Dauer and Przedborski 
2003). The majority of the PD cases are 
sporadic (idiopathic) whereas familial 
etiology is found in about 5-10% of 
patients. 
Although the main pathological feature 
of PD is the degeneration of nigrostriatal 
dopaminergic pathway, other regions of 
the CNS are also affected, including LC 
and raphe nuclei. Locus coeruleus contains 
noradrenergic neurons and is located in the 
brainstem. Raphe nuclei are also located in 
the brainstem, and contain neurons using 
5-hydroxytryptamine (5-HT; serotonin) 
as a neurotransmitter.  According to some 
authors the disease may originate from 
nondopaminergic neurons (Braak et al. 
2004). Braak and colleagues (Braak et al. 
2003; Braak et al. 2004) suggest a scheme 
of six stages for the progression of PD 
pathology in the human brain. According 
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to this scheme, the sporadic PD starts 
from the nondopaminergic structures of 
lower brain stem or olfactory bulb, and 
progresses upward to the cerebral cortex. 
Lewy bodies or Lewy neurites are first 
detected in the dorsal motor nucleus of 
vagal nerve, and in the anterior olfactory 
structures. The fi rst pathological changes 
are found in asymptomatic persons. As 
disease progresses, the Lewy pathology 
spreads gradually into the SN and 
amygdala, and the clinical symptomps 
become evident. At final stages of PD, 
the pathology progresses to the neocortex 
(Braak et al. 2004).  Recently, Braak’s 
scheme has been critically discussed 
(Burke et al. 2008); and evidently the 
relation between abnormal α-synuclein 
immunostaining in the human brain 
and the progression of PD needs further 
studies.  
1.4.1. Mechanisms of dopaminergic 
neurodegeneration in PD
Why are the nigral dopaminergic neurons 
especially vulnerable? Current knowledge 
of the molecular mechanisms leading to 
the degeneration and death of midbrain 
dopaminergic neurons is relatively limited. 
Evidently aging is a major risk factor for 
neurodegenerative diseases, including 
PD. Molecular alterations which are seen 
in normal aging, including increased 
oxidative stress, damaged proteins and 
nucleic acids are amplifi ed in the affected 
neuronal populations in neurodegenerative 
diseases (Mattson and Magnus 2006). 
Oxidative stress resulting from 
the oxidation of dopamine is the major 
hypothesis explaining the endogenous 
vulnerability of mDA neurons (Ahlskog 
2007). Dopamine metabolism creates 
reactive oxygen species (ROS), including 
superoxide anions, dopamine-quinones 
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and hydroxyl radicals which create 
oxidative stress in the cell, by damaging 
proteins, lipids and DNA (Lotharius and 
Brundin 2002). Nigral dopaminergic 
neurons contain neuromelanin, which 
binds iron and may thus facilitate 
oxidation reactions (Ahlskog 2007). 
Subsequently, dopaminergic neurons 
need high antioxidant capacity for the 
protection against oxidative stress and cell 
death. Reduced levels of glutathione, an 
antioxidant, and high levels of oxyradical 
products have been found in the brains 
of PD patients (Dauer and Przedborski 
2003). 
Mitochondrial dysfunction may 
have a major role in the development 
of PD pathology (Mattson et al. 2008). 
Significantly reduced activity of 
mitochondrial respiratory chain complex I 
has been detected in the SN of PD patients 
(Schapira et al. 1989). Furthermore, 
deletions in the mitochondrial DNA 
(mtDNA) leading to functional defi ciences 
of the respiratory chain are signifi cantly 
increased in substantia nigra neurons of 
aged PD patients (Bender et al. 2006). 
MPTP toxin, which causes degeneration 
of nigrostriatal system and PD-like 
symptoms (see 1.4.2.) (Langston et 
al. 1984) selectively inhibits complex 
I function suggesting that complex 
I impairment has a major role in the 
disease. The inhibition of complex I leads 
to ROS production and oxidative stress, 
and induces further alterations in the 
mitochondria (Schapira 2008). Functional 
impairment of the ubiquitin proteasome 
system is also related to the PD pathology 
(Dauer and Przedborski 2003). Decreased 
activity of ubiquitin proteasome complex 
has been detected in the SN of PD patients 
(McNaught et al. 2003). 
Apoptotic cell death and activation 
of caspases are found in PD pathology 
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(Vila and Przedborski 2003). Another 
typical feature of PD pathology is 
infl ammation. Even in the normal brain, 
the density of microglial cells is high in 
the SN (Teismann et al. 2003). Activated 
microglia and astrocytes (Hirsch et al. 
2005; Teismann et al. 2003) and increased 
levels of proinfl ammatory cytokines have 
been detected in the brain of PD patients 
(Hirsch et al. 2005). However, the role 
of inflammation in the disease process 
is unclear. Although usually considered 
as detrimental, gliosis may also have 
protective effects on mDA neurons. 
Glial cells may secrete trophic factors 
and protect against ROS (Teismann et al. 
2003).
One possible cause for the develop-
ment of PD and other neurodegenerative 
diseases is the shortage of neurotrophic 
factors in the brain. Decreased GDNF 
levels have been detected in the SN of PD 
patients (Chauhan et al. 2001) and also in 
the striatum and SN of aged rats (Yurek 
and Fletcher-Turner 2001). Also the levels 
of BDNF and NGF are reduced in the 
SN of PD patients (Howells et al. 2000; 
Mogi et al. 1999; Parain et al. 1999). 
However, direct link between the lack of 
neurotrophic factors or their receptors and 
the development of neurodegenerative 
diseases has not been found.
Since the nigrostriatal dopaminergic 
pathway is degenerated in sporadic as well 
as familial forms of PD, it is assumed that 
common molecular mechanisms function 
behind the both etiologies. Several 
(currently 13) genetic loci have been 
linked to PD, and mutations in α-synuclein, 
parkin, PINK1 (PTEN-induced putative 
kinase 1), DJ-1 and LRRK2 (leucine-rich 
repeat kinase 2) are clear genetic causes 
of PD (Thomas and Beal 2007). Alpha-
synuclein is enriched in presynaptic 
nerve terminals, where it apparently has 
a role in vesicle recycling and dopamine 
neurotransmission (Moore et al. 2005). 
The protein is natively unstructured and 
prone to fi bril formation and subsequent 
aggregation. However, the mechanism 
connecting fibrillar α-synuclein to the 
dysfunction and death of mDA neurons 
have not been resolved (Moore et al. 2005; 
von Bohlen und Halbach 2004). Parkin 
is an ER-associated E3 ubiquitin ligase 
(Imai et al. 2000), which targets misfolded 
proteins to the ubiquitin-proteasome 
pathway for degradation. The expression 
of Parkin is induced by ER stress, 
suggesting that Parkin has a role in the 
adaptation to ER stress (Kim et al. 2008). 
Parkin is also translocated to mitochondria 
where it seems to affect mitochondrial 
fission/fusion together with PINK1 
(Van Laar and Berman 2009). DJ-1 is a 
mitochondrial protein which presumably 
functions as an antioxidant (Thomas 
and Beal 2007). LRRK2 is multidomain 
protein which has a role in synaptic 
vesicle recycling and in the functions 
of mitochondria, Golgi and lysosomes 
(Thomas and Beal 2007). In summary, the 
known genetic causes of PD suggest two 
main pathways for PD pathogenesis: 1) 
Mitochondrial dysfunction and oxidative 
stress, in which the antioxidant capacity 
of the cell is unable to neutralize ROS; 2) 
dysfunction of the ubiquitin proteasome 
system and impaired degradation of 
misfolded proteins. These pathways are 
presumably inter-related, which affects 
disease progression. Whether ER stress 
contributes to the PD progression or 
has a protective role against disease 
development is currently unclear (Kim et 
al. 2008).
Review of the literature
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1.4.2. Modelling of PD 
Animal and cell culture models mimicking 
the PD pathology seen in humans 
are valuable tools to study molecular 
mechanisms behind the disease. Toxin-
induced models are used to study the 
pathogenesis of PD at cellular and 
molecular level, in vitro and in vivo. The 
most commonly used toxins are 6-OHDA 
and MPTP (Table 2). They are used 
especially in preclinical studies of novel 
therapeutic agents. MPTP was discovered 
at early 1980’s as a contaminant of a 
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Table 2. PD models in rodents.
Toxin models Reference Cellular effects of  the toxin Toxin-induced 
phenotype








motor dysfunction, no 
inclusion bodies
MPTP/MPP+ 
(mouse; used also in 
non-human primates)
Jenner 2008; 
Langston et al. 
1983
Mitochondrial respiratory 







Reference Known function of the 





A53T or A30P 
transgene)
Giasson et al. 
2002; Lee et 
al. 2002
Associates with synaptic 
terminals, vesicle recycling
Motor dysfunction, 
no clear degeneration 
of nigrostriatal DA 
neurons, intracellular 
inclusions
DJ-1 knockout Chen et 
al. 2005; 





no clear degeneration 
of nigrostriatal DA 
neurons, elevated 
striatal DA and DA 
reuptake
Parkin knockout Goldberg et al. 
2003
E3 ubiquitin ligase Motor dysfunction, 
no clear degeneration 
of nigrostriatal DA 
neurons, increased 
striatal DA content, 
reduced striatal neuron 
excitability
PINK1 knockout Gautier et al. 
2008; Kitada et 
al. 2007
Serine/threonine 
kinase, fi ssion/fusion of 
mitochondria
No clear degeneration 
of nigrostriatal DA 
neurons, reduced 







Hwang et al. 
2005
Homeodomain transcription 






knockout in mDA 
neurons (MitoPark)
Ekstrand et al. 
2007
Mitochondrial transcription 
factor (Reduced mtDNA 









synthetic narcotic, and caused severe PD-
like symptoms in drug users (Langston et 
al. 1983). MPTP damages the nigrostriatal 
dopaminergic pathway in a manner similar 
to that of seen in the PD patients, but 
without classical Lewy body formation 
(Dauer and Przedborski 2003). MPTP 
readily crosses the blood-brain barrier 
(BBB) and it is metabolized in astrocytes 
to toxic 1-methyl-4-phenylpyridinium 
(MPP+) which is subsequently released 
and taken up by dopaminergic neurons. 
MPP+ inhibits the complex I in the 
mitochondrial electron transport chain, 
which results in ROS production, oxidative 
stress, energy depletion, and apoptotic cell 
death. MPTP is used commonly in mice 
(since rats are less sensitive to it) and non-
human primates to test novel treatment 
strategies for PD. 
Exposure to some environmental 
toxins, including pesticide rotenone and 
herbicide paraquat, increases the risk of 
PD in humans. These toxins have also been 
used in modelling of PD in vitro and in vivo 
(Bove et al. 2005). Lipopolysaccharide 
(LPS), a component of the outer membrane 
of Gram-negative bacteria, is also used 
in a rodent model of PD (Gao et al. 
2002; Herrera et al. 2000). Discovery of 
familial PD mutations has opened a way 
to develop genetic models of PD (Table 
2). Deletion of mitochondrial transcription 
factor A (Tfam) in mDA neurons resulted 
in progressive PD symptomps in mice 
(Ekstrand et al. 2007). Interestingly, 
transgenic expression of mutant human 
LRRK2 caused Parkinsonism-like 
phenotype in Drosophila (Liu et al. 2008). 
Studies on the overexpression of mutated 
human α-synuclein in mice have resulted 
only mild, if any, effects on mDA neurons 
(Schneider, Zufferey et al. 2008).  
1.4.3. 6-OHDA model of PD
6-OHDA is a structural analog of 
dopamine and noradrenaline, and it 
selectively destroys cathecolaminergic 
neurons. It is taken up by dopaminergic or 
noradrenaline transporters (DAT or NAT, 
respectively) into the cell. 6-OHDA can 
affect all cathecolamine neurons in the 
body, and systemic injection of 6-OHDA 
induces degeneration of sympathetic 
nerve endings (Blum et al. 2001). Since 
6-OHDA does not cross BBB, it has to 
be injected directly into the brain to target 
cathecolaminergic pathways. The 6-OHDA 
lesion model of PD is commonly applied 
on rats. In order to target the nigrostriatal 
dopaminergic pathway, 6-OHDA can 
be injected either into the striatum, SN, 
or MFB (Fig. 3A). The specificity of 
6-OHDA for dopaminergic neurons is 
increased with noradrenaline transport 
blockers, which inhibit 6-OHDA uptake 
by noradrenergic neurons (Deumens et al. 
2002). The injection site affects severity 
of the lesion; injection into the MFB or 
SN induces pronounced destruction of 
dopaminergic neurons, whereas 6-OHDA 
injection into the striatum leads to more 
protracted degeneration (Deumens et al. 
2002). After striatal injection, the axon 
terminals of mDA neurons are destroyed 
fi rst, and the axonal degeneration gradually 
proceeds towards cell bodies in the SNpc. 
This retrograde degeneration may continue 
up to 8-16 weeks (Sauer and Oertel 1994). 
Usually 6-OHDA toxin is injected into the 
brain unilaterally, which creates dopamine 
imbalance between the hemispheres. The 
severity of the lesion can be estimated 
by measuring the rotational behaviour 
of rats after administration of drugs 
which stimulate either dopamine release 
(e.g. amphetamine; rotation towards the 
lesion), or dopamine receptor activity 
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(e.g. apomorphine; rotation away from 
the lesion) (Ungerstedt and Arbuthnott 
1970; Deumens et al. 2002). Characteristic 
feature of PD, the formation of Lewy 
bodies, has not been reliably detected in 
the 6-OHDA model of PD (Bove et al. 
2005). 
The mechanism of 6-OHDA toxicity 
is not completely known. However, it is 
largely based on oxidative stress: ROS and 
quinones derived from 6-OHDA diminish 
the antioxidant capacity of the cell, 
resulting oxidative damage on proteins, 
lipids and DNA (Schober 2004). 6-OHDA 
injection also increases iron levels in the 
SN, which further induces generation of 
ROS (Blum et al. 2001). 6-OHDA has been 
shown to inhibit mitochondrial respiratory 
chain complex I suggesting that it impairs 
mitochondrial function in cells (Glinka 
and Youdim 1995), which creates ROS, 
reduces ATP levels and leads to cell death. 
Apoptosis markers including cleaved 
caspase-3 and condensed chromatin, are 
detected in cells treated with 6-OHDA. 
It has been shown that 6-OHDA induced 
cell death depends on de novo protein 
synthesis. Transcription factor CHOP (C/
EBP homologous protein) has been shown 
to mediate 6-OHDA induced apoptosis 
in vivo (Silva et al. 2005). CHOP is 
upregulated in ER stress induced unfolded 
protein response (UPR; see 1.5.2.) and 
regulates expression of proapoptotic 
genes (Szegezdi et al. 2006b). 6-OHDA 
treatment upregulated genes involved in 
the UPR and ER stress, including CHOP, 
in PC12 cells (Ryu et al. 2002) and in 
MN9D cells (Holtz and O’Malley 2003). 
However, the role of UPR and ER stress in 
the 6-OHDA toxicity in vivo is still unclear 
(Silva et al. 2005). 6-OHDA injection also 
induces gliosis and astrocytic activation 
(Bove et al. 2005; Henning et al. 2008).
6-OHDA model is commonly used 
in preclinical studies to test the potency 
of novel molecules for treatment of PD. 
When designing an experimental setup for 
6-OHDA rat model of PD, several aspects 
have to be considered, including the site of 
6-OHDA injection (striatum, SN or MFB), 
the site of protein delivery (striatum, SN 
or ventricle), and the method of protein 
delivery (single/multiple injection(s), 
continuous infusion by pumps, protein 
secreting cell grafts or viral vectors). 
Neuroprotective effects of a trophic factor 
can be studied by injecting the factor 
before the toxin. More challenging is the 
experimental setup of “neurorestoration” 
in which the lesion is induced first and 
the trophic factor injected afterwards. The 
latter model resembles more closely to PD, 
in which the neurodegeneration is severe 
before the clinical symptoms appear and 
treatment is started. Several trophic factors 
have neuroprotective effects in PD models 
(Table 1), whereas only GDNF and NRTN 
have well-established neurorestorative 
effects on mDA neurons in PD models 
shown by several independent research 
groups.
 
1.4.4. GDNF is protective and restorative 
in PD models
Neurotrophic activity of GDNF has been 
intensively studied in rodent and primate 
models of PD. These studies have proved 
the potency of GDNF as a neurotrophic 
factor for midbrain dopaminergic 
neurons. One of the fi rst studies showed 
the neuroprotective and neurorestorative 
effects of GDNF on adult nigrostriatal 
dopaminergic system in mouse MPTP 
model of PD (Tomac et al. 1995a). GDNF 
injected into the striatum or SN before 
MPTP or into the striatum after MPTP 
was able to increase dopamine levels, 
TH-positive fi bre densities and improve 
motor behaviour (Tomac et al. 1995a). 
GDNF injected into the SN was unable 
Review of the literature
19
to induce sprouting of dopaminergic 
fibers in the striatum when given after 
MPTP suggesting a target-derived role 
for GDNF (Tomac et al. 1995a). GDNF 
injections into the SN also protected 
midbrain dopaminergic neurons from 
MFB axotomy-induced degeneration in 
rats (Beck et al. 1995). 
GDNF has signifi cant neuroprotective 
and neurorestorative effects against 
striatal 6-OHDA lesion in rats, as shown 
by several studies. Striatally injected 
GDNF induced functional recovery of 
the midbrain dopaminergic system and 
sprouting of dopaminergic fibers after 
striatally injected 6-OHDA (Aoi et al. 
2000; Rosenblad et al. 1998). Combination 
of intraventricular and intrastriatal GDNF, 
or intraventricular GDNF alone induced 
protection and restoration of the mDA 
system when given after striatal 6-OHDA 
lesion in rats (Kirik et al. 2001; Rosenblad 
et al. 1999). Continuous infusion of GDNF 
over the SN prevented nigral death and 
atrophy induced by intrastriatal 6-OHDA 
(Rosenblad et al. 2000; Sauer et al. 1995). 
However, GDNF injected close to the SN 
did not preserve dopaminergic innervation 
in the striatum, nor induced functional 
recovery after intrastriatal 6-OHDA (Sauer 
et al. 1995; Winkler et al. 1996). 
GDNF shows protect ive  and 
restorative activities on mDA neurons 
also in PD models in which 6-OHDA is 
given into the MFB or SN. GDNF was 
neuroprotective when it was given into 
the SN before nigral 6-OHDA (Kearns et 
al. 1997), or when it was given into the 
SN and lateral ventricle before 6-OHDA 
injection into the MFB (Sullivan et al. 
1998). Consistently, GDNF-secreting 
intranigral grafts were protective against 
6-OHDA injection into MFB (Åkerud 
et al. 1999). GDNF induced functional 
recovery of nigrostriatal system when it 
was delivered into the SN after 6-OHDA 
lesion in the MFB (Bowenkamp et al. 
1995; Hoffer et al. 1994), or after 6-OHDA 
lesion in the SN (Kearns and Gash 1995). 
The potency of GDNF has also been 
shown in unilateral and bilateral MPTP 
models of PD in non-human primates 
(Costa et al. 2001; Gash et al. 2005; Gash et 
al. 1996; Grondin et al. 2002; Zhang et al. 
1997). GDNF delivered either intranigral, 
intracaudal or intracerebroventricular 
(ICV) route induced functional recovery 
of MPTP induced hemiparkinsonism in 
monkeys (Gash et al. 1996; Zhang et al. 
1997; Gash et al. 2005). 
 
1.4.5. Neurotrophic factors as 
therapeutic proteins for PD 
Currently, no PD therapies exist that could 
stop the degeneration of dopaminergic 
neurons or induce neuronal recovery. 
All therapies available are directed to 
alleviate the disease symptoms, usually by 
correcting dopamine neurotransmission in 
the striatum. Levodopa (3,4-dihydroxy-
L-phenylalanine), an intermediate of 
dopamine biosynthesis, is widely used 
(Lewitt 2008), but it usually causes 
severe side effects after prolonged use. 
Thus, novel treatment strategies are 
needed. Since neurotrophic factors have 
many beneficial effects on neurons, 
they may be useful in the treatment of 
neurodegenerative diseases, including 
PD, AD, amyotrophic lateral sclerosis 
(ALS) and spinal cord injury. Although 
lack of NTFs have not been shown to 
directly cause neurodegenerative diseases, 
the levels of NTFs are decreased in 
neurodegeneration (Chao et al. 2006). 
Thus, delivery of neurotrophic factors 
may help to resore the NTF deficiency 
in disease. Also the synergistic effects of 
neurotrophic factors may have clinical 
relevance. 
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Method of delivery is problematic 
in the NTF therapy, as proteins do not 
cross BBB. Different delivery methods, 
including gene therapy by viral vectors 
or direct protein infusion are under 
investigation. Only two NTFs, GDNF and 
NRTN have been taken to clinical trials on 
PD patients. However, results from these 
trials have been somewhat disappointing. 
Intracerebroventricular infusion of GDNF 
created side-effects, and did not improve 
Parkinsonism (Nutt et al. 2003). The 
infused GDNF did apparently not reach 
the targets SN and putamen (Kordower 
et al. 1999; Nutt et al. 2003). In contrast, 
direct infusion of GDNF into the putamen 
of PD patients led to signifi cant clinical 
improvement without serious side-effects 
(Gill et al. 2003; Patel et al. 2005; Slevin 
et al. 2005). A post-mortem study of one 
patient showed sprouting of dopaminergic 
fi bers induced by intraputamenal GDNF 
(Love et al. 2005). Differently from these 
encouraging phase I results, a double 
blind phase II study showed low clinical 
efficacy of GDNF, and formation of 
GDNF function blocking antibodies (Lang 
et al. 2006). The clinical trials with GDNF 
are currently interrupted. 
Although phase I clinical trial of 
NRTN gene therapy on PD patients using 
AAV2-vector based delivery into the 
putamen showed safety, tolerability and 
potential efficacy (Marks et al. 2008), 
recently completed phase II study did not 
show difference between patients treated 
with CERE-120 and the control group 
(Ceregene Inc., press release on November 
26th, 2008). Thus, it is important to search 
and study novel neurotrophic factors for 
mDA neurons that could also be applied 
to clinic.
1.5. Mesencephalic astrocyte-derived 
neurotrophic factor (MANF)
1.5.1. MANF is a survival factor for 
midbrain dopaminergic neurons
The first report of human arginine rich 
protein (ARP) gene described it as an 
oncogene mutated in renal cell carcinomas 
(Shridhar et al. 1996b). ARP (or ARMET; 
arginine-rich, mutated in early stage 
tumors) was later shown to encode protein 
with neurotrophic effects, and the protein 
was re-named as mesencephalic astrocyte-
derived neurotrophic factor (Petrova et al. 
2003). 
MANF was originally identified 
from the culture medium of rat type-1 
astrocyte ventral mesencephalic cell line 
1 (VMCL1) based on its trophic effects on 
cultured embryonic dopaminergic neurons 
(Petrova et al. 2003). Previously it was 
shown that the culture medium of VMCL1 
cells supported the survival and promoted 
the neurite outgrowth of embryonic 
mesencephalic dopamine neurons in 
culture (Panchision et al. 1998). After 
sequential purifi cation steps, the survival 
promoting, active rat protein was isolated 
and found homologous to the predicted 
human ARP protein of 234 amino acids 
with an amino-terminal arginine rich 
region (NP_006001) (Shridhar et al. 
1996b). ARP protein had never been 
expressed in vitro or purifi ed from tissue. 
According to the report by Petrova et 
al. (2003), the amino acid number 56 
of human ARP equals to the initiation 
methionine of human MANF. Thus, human 
MANF consists of 179 amino acids (amino 
acids 56-234) and lacks the arginine-rich 
sequence (amino acids 1-55) of human 
ARP. The amino-terminal arginine-tract 
of ARP is apparently not synthesized in 
vivo (Petrova et al. 2003). Thus, ARP or 
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ARMET name is misleading, and we 
prefer the name MANF. MANF protein 
is highly conserved from C. elegans and 
D. melanogaster to human with eight 
conserved cysteine residues of similar 
spacing (Petrova et al. 2003; Shridhar et 
al. 1996b).
Human MANF (ARMET, ARP) gene 
is located in the short arm of chromosome 
3 (3p21.1) (Shridhar et al. 1996b). 
Several reports associated mutations in 
the arginine-rich region of ARP with 
different forms of cancer (Shridhar et al. 
1996a; Shridhar et al. 1996b; Shridhar 
et al. 1997). However, these have been 
contrasted by other studies showing that 
the variations in the arginine-rich region 
represent normal polymorphisms (Evron 
et al. 1997; Piepoli et al. 2006; Tanaka et 
al. 2000). 
According to Petrova et al. (2003) 
human MANF is a 20 kDa, glycosylated 
(sialylated) protein. Recombinant human 
MANF promoted the survival and induced 
sprouting of E14 rat dopaminergic 
neurons in culture (Petrova et al. 2003). 
The authors reported that the survival 
promoting activity of MANF was 
specifi c on dopaminergic neurons versus 
GABAergic or serotonergic neurons 
present in the embryonic mesencephalic 
cultures, although MANF also increased 
general viability of cultured mesencephalic 
neurons. The authors suggested that 
MANF can maintain TH expression 
in dopaminergic neurons but not the 
expression of glutamate decarboxylase 
(GAD) or tryptophan hydroxylase (TPH) 
in GABAergic or serotonergic neurons, 
respectively. MANF also increased the 
survival of cultured dorsal root ganglion 
(DRG) neurons, but not the survival of 
sympathetic or cerebellar granule neurons 
(Petrova et al. 2003). Extracellularly 
applied MANF was reported to enhance 
the frequency of GABAA-receptor 
mediated inhibitory post-synaptic currents 
in dissociated postnatal rat dopaminergic 
neurons and in midbrain slices (Zhou et al. 
2006). Thus, GABA-mediated inhibitory 
effect on neuronal fi ring may contribute 
the neuroprotective action of MANF on 
dopaminergic neurons (Zhou et al. 2006).
1.5.2. MANF is induced by ER stress 
and protects against ischemic cell death 
Recent studies indicate that MANF is 
an endoplasmic reticulum (ER) stress 
response protein (Apostolou et al. 2008; 
Lee et al. 2003; Mizobuchi et al. 2007; 
Tadimalla et al. 2008). Accumulation of 
unfolded proteins in the ER causes ER 
stress and the induction unfolded protein 
response (UPR), which is a signal-
transduction pathway that counteracts 
ER stress (Fig. 4) (Szegezdi et al. 2006b). 
By UPR, the protein folding capacity 
and degradation of misfolded proteins 
is increased in the cell, and protein 
translocation across the ER membrane is 
reduced. Molecular chaperones function to 
refold proteins, and ER associated protein 
degradation (ERAD) removes misfolded 
proteins. Three main UPR pathways 
are mediated by the ER transmembrane 
receptors inositol-requiring enzyme 1 
(IRE1), pancreatic ER kinase (PKR)-
like ER kinase (PERK) and activating 
transcription factor 6 (ATF6) (Szegezdi 
et al. 2006b). Also the transcription factor 
X-box binding protein 1 (XBP1) regulates 
UPR target gene expression (Szegezdi et 
al. 2006b).
Microarray analysis of mouse 
embryonic fibroblasts treated with 
tunicamycin, an inhibitor of N-linked 
glycosylation and ER stress agent, 
revealed Armet (Manf) as an ER stress 
response gene (Lee et al. 2003). Armet 
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expression was upregulated in wild-type 
cells but not in XBP1-/- cells when ATF6 
was knocked down by small interfering 
RNA (siRNA), indicating that Armet 
expression requires either XBP1 or ATF6. 
Thus, Armet may have a role in the quality 
control of proteins during ER stress (Lee 
et al. 2003). In consistence, another 
microarray study reported upregulation 
of Armet by ATF6 expression in the heart 
of ATF6 transgenic mouse (Belmont et 
al. 2008). Armet was also upregulated in 
pancreatic β cells of insulin-Akita mouse 
(Mizobuchi et al. 2007). These cells 
undergo continuous ER stress caused by 
the accumulation of unfolded proinsulin. 
The expression of Armet was upregulated 
by ER stress response element-II (ERSE-
II) located in the Armet promoter 
(Mizobuchi et al. 2007). Transcription 
factors XBP1, ATF6, CBF/NF-Y and 
luman/CREB3 are known to bind ERSE-II 
(Liang et al. 2006; Yamamoto et al. 2004) 
and may thus regulate Armet expression 
(Mizobuchi et al. 2007). Armet was also 
upregulated in human osteosarcoma U2OS 
and embryonic kidney HEK293 cells by 
different UPR inducers (Apostolou et al. 
2008). Ischemia is known to induce ER 
stress response (Szegezdi et al. 2006a). 
In line, hypoxia induced upregulation of 
Manf in HeLa cells (Romero-Ramirez et 
al. 2004), and Manf was also upregulated 
in the mouse myocardium in vivo after 
myocardial infarction (Harpster et al. 
2006; Tadimalla et al. 2008). 
Knockdown of Armet expression 
by siRNA increased the susceptibility of 
HeLa cells to tunicamycin-induced death 
(Apostolou et al. 2008). It also induced 
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Figure 4. Activation of the UPR. Transmembrane receptors PERK, ATF6 and IRE1 are normally 
associated with ER chaperone Grp78 (glucose regulated protein 78; BiP). Accumulation of 
unfolded proteins dissociates Grp78, and triggers UPR. Activated PERK phosphorylates 
eukaryotic initiation factor 2 (eIF2), which blocks protein translation. Phosphorylation eIF2 
enables translation of transcription factor ATF4. ATF4 induces transcription of genes required 
for the restoration of ER balance. Activated ATF6 regulates expression of ER chaperones and 
XBP1. XBP1 mRNA is spliced by IRE1. Spliced XBP1 protein (sXBP1) controls transcription of 
chaperones and genes involved in protein degradation. Reprinted by permission from Macmillan 
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expression of UPR response factors, which 
was further aggravated by tunicamycin 
treatment. In line, overexpression of 
Armet in U2OS osteosarcoma cells made 
the cells more resistant to tunicamycin-
induced death, supporting the role of 
ARMET as a protective protein against 
ER stress-induced cell death (Apostolou 
et al. 2008). Importantly, addition of 
recombinant MANF protein to the culture 
medium of cardiac myocytes prevented 
the simulated ischemia induced cell 
death in vitro (Tadimalla et al. 2008). 
Furthermore, MANF protein was recently 
shown to protect against ischemic 
brain injury induced by middle cerebral 
artery occlusion (MCAO) in rats in vivo 
(Airavaara et al. 2009). The proposed 
protective role of MANF in ER stress and 
in relation to our data is discussed in more 
detail in the Discussion.  
1.6. Saposin-like proteins (SAPLIPs)
1.6.1. SAPLIPs have diverse functions 
The family of saposin-like proteins 
is defined by a characteristic three-
dimensional fold, which consists of 
four to five α-helices connected by 
three disulphide bridges in a globular 
conformation (Fig. 5B). The disulphide 
bridges are formed by six cystine residues, 
spacing of which is conserved in the 
SAPLIP primary structure, making the 
saposin-fold highly stable (Bruhn 2005). 
SAPLIPs are highly variable in amino 
acid sequences with identities below 25-
30%. The group is named according to the 
sphingolipid-activator proteins (saposins) 
A-D which function as co-factors of 
glycosphingolipid (GSL) degradation by 
GSL hydrolases in the endosomes and 
lysosomes. A common feature of SAPLIPs 
is their ability to interact with membranes 
or lipids (Bruhn 2005). 
SAPLIPs are found from primitive 
amoebazoans to mammals, and they 
exert various functions. Mammalian NK-
lysin (Andersson et al. 1995) and human 
granulysin (Jongstra et al. 1987; Stenger 
et al. 1998) are produced by natural killer 
(NK) cells and cytotoxic T-lymphocytes, 
and function as antimicrobial proteins. 
Entamoeba histolytica, a protozoan 
parasite, synthesizes antimicrobial 
saposin-like amoebapores (Keller et al. 
1989). Amoebapores form ion channels 
on the membrane of a target cell by 
oligomerization, which leads to cytolysis 
and death (Hecht et al. 2004; Zhai and 
Saier 2000). Surfactant protein B (SP-B), 
a water insoluble and dimeric SAPLIP, 
reduces surface tension in the air/liquid 
interface in alveolar ducts (Cochrane and 
Revak 1991). 
Some of the SAPLIPs, including 
prosaposin (PSAP) and saposin C (SapC; 
see 1.6.2. for more details) have also 
neurotrophic activities. Overexpression 
of ER-resident MSAP (myosin regulatory 
light chain (MRLC)-interacting (MIR)-
interact ing saposin- l ike  prote in; 
Cnpy2) induced neurite outgrowth in 
neuroblastoma and phaeochromocytoma 
cell lines (Bornhauser et al. 2003) 
and migration of glioma cells in vitro 
(Bornhauser and Lindholm 2005). 
Canopy1, a zebrafi sh SAPLIP and an ER 
resident protein, regulates FGF signalling 
in the midbrain-hindbrain boundary 
(MHB) during embryonic development 
and interacts with a fibroblast growth 
factor receptor 1 (FGFR1) (Hirate and 
Okamoto 2006). 
Although most of the SAPLIPs are 
single-domain proteins, a saposin-like 
domain may also belong to a multidomain 
protein. Leukocytic acyloxyacyl hydrolase 
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(AOAH), a two-subunit lipase protein, 
cleaves acyl chains of bacterial LPS, thus 
reducing LPS toxicity. The amino (N)-
terminal saposin-like domain of AOAH 
contributes to intracellular targeting, 
LPS recognition and catalytic function of 
AOAH. Acid sphingomyelinase (ASM) 
participates in lysosomal sphingolipid 
degradation (Ponting 1994), and its 
saposin-like domain stimulates the 
enzymatic activity and stabilizes protein 
structure (Kolzer et al. 2004). Saposin-
like domain (swaposin) is also found in 
prophytepsin, a plant aspartic protease 
(Kervinen et al. 1999). 
1.6.2. Sphingolipid activator proteins 
(saposins) 
Saposins A, B, C and D (SapA, B, C and 
D) are non-enzymatic proteins which 
function as co-factors of sphingolipid 
degradation in the lysosomes (Kishimoto 
et al. 1992). They are small (~80 aa; 
9 kDa), heat-stable glycoproteins, 
and ubiquitously expressed, with high 
levels in the spleen, liver and kidney 
(Kolter and Sandhoff 2005). Each of the 
saposins A-D promotes the degradation of 
particular GSLs. Functional defi ciencies 
of SapA-D lead to sphingolipid storage 
diseases characterized by accumulation 
of lipid aggregates within the lysosomes. 
Neurological defects are usually related to 
these diseases (Sun et al. 2008; Kolter and 
Sandhoff 2005). In the endocytic pathway, 
saposins facilitate the association of lipid 
antigens to cluster of differentiation 1 
(CD1) molecules, which present antigens 
to natural killer T cells (Winau et al. 2004; 
Yuan et al. 2007; Zhou et al. 2004). Sap-B 
has been shown to interact with coenzyme 
Q10, a component of mitochondrial 
respiratory chain and an antioxidant (Jin 
et al. 2008). 
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Figure 5. A) Scematic presentation of 
prosaposin, from which saposins A-D 
are processed. Signal sequence (pre) and 
glycosylation sites (Y) are indicated. B) 
Saposin A monomer (Ahn et al. 2006). C) 
Saposin B homodimer with phospholipid (Ahn 
et al. 2003). D) Saposin C homodimer at pH 4 
as a domain-swapped dimer (Rossmann et al. 
2008). 
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Saposins A-D are synthetized as a 
precursor protein, prosaposin (PSAP), 
from which they are proteolytically 
cleaved in late endosomes or lysosomes 
(Fig. 5A) (Kishimoto et al. 1992). PSAP-
defi cient mice die either shortly after birth 
or survive for about fi ve weeks (Fujita et al. 
1996), accumulate glycosphingolipids in 
cells and show complex neurodegeneration 
(Fujita et al. 1996). PSAP is secreted into 
body fl uids, including cerebrospinal fl uid 
and seminal plasma (Kishimoto et al. 
1992). 
Neurotrophic activity of PSAP and 
SapC has been mainly studied by O’Brien 
and colleagues. According to these 
studies, PSAP and SapC increased neurite 
outgrowth in human neuroblastoma 
NS20Y cells in vitro (O’Brien et al. 
1994). PSAP also promoted the survival 
of cultured hippocampal neurons and 
the regeneration of sciatic nerve after 
transection (Kotani et al. 1996a; Kotani 
et al. 1996b). The neurotrophic activity 
of PSAP was located into the amino-
terminal domain of SapC (Campana et al. 
1996; O’Brien et al. 1994; O’Brien et al. 
1995; Qi et al. 1996), and a corresponding 
peptide derived from SapC was shown to 
rescue dopaminergic cells in the SN when 
given subcutaneously after MPTP in a 
mouse model of PD (Liu et al. 2001). This 
peptide also prevented ischemia-induced 
learning disability and hippocampal 
neuronal loss in vivo in gerbils (Sano et 
al. 1994). More recent study shows anti-
apoptotic activity of SapC that is mediated 
by PI3K (phosphatidylinositol 3’-kinase)/
Akt (protein kinase B) pathway in prostate 
cancer cells in vitro (Lee et al. 2004). 
The putative receptor and signalling 
pathways of PSAP and SapA-D still 
remain unclear. Extracellular PSAP can be 
endocytosed by low-density lipoprotein 
receptor-related protein (LRP) or by 
mannose-6-receptor (M-6-R) in murine 
embryonic fi broblasts or taken up by LRP 
or M-6-R from bloodstream to the liver 
in vivo (Hiesberger et al. 1998). O’Brien 
and colleagues presented evidence that 
receptor for PSAP is G-protein coupled 
(Hiraiwa et al. 1997), and PSAP associates 
with gangliosides on neuroblastoma cell 
membranes in vitro (Misasi et al. 1998). 
Recently, PSAP signalling was reported to 
occur through lipid rafts in vitro (Sorice et 
al. 2008).
 
1.6.3. NK-lysin and granulysin
NK-lysin and granulysin are antimicrobial 
defence proteins of innate immune 
system which have a saposin-like three-
dimensional fold. NK-lysin was originally 
isolated from porcine small intestine based 
on its antibacterial activity (Andersson 
et al. 1995). NK-lysin is also cytotoxic 
against fungal cells and tumour cell 
lines (Andersson et al. 1995). Human 
granulysin is structurally and functionally 
related to porcine NK-lysin, although 
identity between the amino acid sequences 
of these two proteins is only 35% (Peña 
and Krensky 1997). Porcine NK-lysin 
and human granulysin are basic proteins 
of 78 and 74 amino acids, respectively. 
Granulysin is synthetized as a precursor 
of 15 kDa which is secreted and processed 
into 9 kDa form in the acidic environment 
of cytolytic granules (Hanson et al. 1999). 
Mammalian homologues to NK-lysin have 
been characterized from equine (Davis 
et al. 2005) and bovine (Endsley et al. 
2004), whereas mouse does not have an 
orthologue (Bruhn 2005). 
Expression of the porcine NK-lysin 
mRNA is induced by interleukin-2 (IL-2) 
treatment in T lymphocytes and NK cells, 
and the protein is usually localized in 
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intracellular granules (Andersson et al. 
1995). Also the bone marrow and spleen, 
which are known to contain high amounts 
of lymphocytes, express NK-lysin mRNA 
(Andersson et al. 1995). Similarly with 
NK-lysin, human granulysin is expressed 
in NK cells and cytolytic T lymphocytes. 
Granulysin mRNA expression starts 
3-5 d after T cell activation (Jongstra et 
al. 1987). The protein is located in the 
cytolytic granules which are exocytosed 
upon antigenic stimulation of T cells. 
Granulysin exerts antimicrobial activity 
against a broad range of Gram-negative 
and Gram-positive bacteria including 
Mycobacterium tuberculosis, fungi and 
parasites (Stenger et al. 1998). In vitro 
studies using human T lymphocyte Jurkat 
cell line have shown that membrane 
disruption by granulysin results to 
ion fluxes, ceramide generation and 
subsequent apoptosis, which is mediated 
by cytochrome c release and activation 
of caspases (Krensky and Clayberger 
2005). A secreted granulysin precursor 
is also active: it induces apoptosis of 
keratinocytes and mediates epidermal 
necrosis related to adverse drug reactions 
in humans (Chung et al. 2008).
1.6.4. Membrane interactions of 
SAPLIPs 
SAPLIPs are usually found in a closed 
conformation with a small hydrophobic 
core. However, structural studies 
indicate that conformational changes 
and oligomerization are important for 
the membrane interaction and function 
of SAPLIPs (Bruhn 2005). For example, 
oligomerization may facilitate pore 
formation or membrane fusion. Membrane 
interactions of SAPLIPs are usually pH-
dependent.
NMR structure of NK-lysin was the 
fi rst SAPLIP structure resolved (see Fig. 
9E in Results) (Liepinsh et al. 1997). 
In this structure, the five amphiphatic 
α-helices form a single globular domain. 
The authors suggest that the positions 
of α-helices may change in membrane 
interactions (Liepinsh et al. 1997). 
Positively charged side chains of arginine 
and lysine residues form an equatorial belt 
around NK-lysin molecule, which may 
interact with negatively charged membrane 
lipid head groups (Liepinsh et al. 1997). 
Similarly with NK-lysin, the crystal 
structure of human granulysin revealed 
a saposin-fold (Fig. 9C) (Anderson et al. 
2003). Granulysin contains fi ve cysteines, 
and two disulfi de bonds connecting helices 
1 and 5, and helices 2 and 3, respectively. 
Positively charged residues distribute 
mostly as a ring around the molecule, 
and the charge distribution steers the 
orientation of granulysin relative to the 
membrane. Lytic process induced by 
granulysin may involve motion of the 
helical regions as “scissors” which would 
expose the hydrophobic inner surfaces of 
granulysin to the membrane (Anderson et 
al. 2003). 
Altough saposins are usually 
monomeric, saposin B crystallized as a 
homodimer with a bound phospholipid 
(Fig. 5C) (Ahn et al. 2003).  In the shell-
like SapB dimer, the monomers adopted 
an open V-shaped conformation and a 
hydrophobic cavity was located between 
the monomers. The authors suggest that 
the conformational change in the SapB 
dimer facilitates lipid access to the inner 
cavity and is important for the lipid 
extraction from membranes (Ahn et al. 
2003). SapB is a lipid-transport protein 
(Vogel et al. 1991), that does apparently 
not bind membranes directly, but extracts 
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GSLs from membranes and forms a 
soluble complex, which is subsequently 
recognized by the lipid degrading enzyme 
(Vaccaro et al. 1999). 
Resembling the SapB dimer structure, 
signifi cant conformational change in the 
NMR structure of monomeric SapC was 
detected in the presence of detergent 
sodium dodecyl sulfate (SDS) (Hawkins 
et al. 2005). In the absence of SDS, SapC 
is in closed conformation (de Alba et al. 
2003). When binding to SDS, the SapC 
monomer opens to a U-shaped tertiary 
structure, in which the hydrophobic pocket 
is exposed to solvent. The hydrophobic 
pocket is likely to contact with membrane 
lipids (Hawkins et al. 2005). 
Saposins function in the acidic 
environment of pH 4.0-5.5 in lysosomes. 
It has been shown that pH affects the 
conformation and activity of saposins. 
SapC participates in vesicle destabilization 
and fusion in a pH-dependent manner 
(Vaccaro et al. 1994). At acidic pH, the 
hydrophobicity of SapA, SapC, and 
SapD are increased, which promotes their 
interaction with membranes (Vaccaro et al. 
1995). Saposins A and C are monomeric 
at neutral pH 7.0, whereas SapA forms 
dimers and SapC trimers at acidic pH 
4.8, in the presence of polyethyleneglycol 
detergent (Ahn et al. 2006). Lysosomal 
lipid-rich acidic environment may induce 
conformational changes in SapA and 
SapC that are needed for their activities 
(Ahn et al. 2006). Recently Rossman et al. 
(2008) crystallized SapC at pH 4.0 in open 
confi guration as domain-swapped dimers, 
which may function in vesicle fusion (Fig. 
5D).
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Aims of the study
2. AIMS OF THE STUDY
Neurotrophic factors, which by defi nition have benefi cial effects on neurons, have been 
acknowledged as potential targets for drug development for neurodegenerative diseases. 
Therefore, it is important to search and study new proteins with neurotrophic effects. The 
starting point to this project was a publication describing MANF, a novel survival factor 
for midbrain dopaminergic neurons (Petrova et al. 2003). Soon thereafter we identifi ed 
conserved dopamine neurotrophic factor (CDNF), a homologous protein for MANF. 
The aim of this work was to characterize the molecular structure, tissue expression and 
potential neurotrophic activities of CDNF and MANF proteins. 
The specifi c aims were:
To characterize the expression of CDNF and MANF in mouse and human tissues.- 
To produce and characterize CDNF and MANF proteins - in vitro.
To study the effect of CDNF protein on midbrain dopaminergic neurons in a rat - 
6-OHDA model of Parkinson’s disease.
To determine the crystal structure of CDNF and MANF proteins, and subsequently - 
elucidate their modes of action.
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Materials and methods
3. MATERIALS AND METHODS
Materials and methods used in this work are described in detail in the original articles. 
The methods are summarized in Table 3, and a short overview is given below. 
Table 3. Methods used in this study.  
Method Article
DNA and RNA methods I II III
RNA isolation and reverse transcription I II
PCR, cloning and DNA sequencing I II III
Northern hybridization II
In situ hybridization I II
Recombinant protein production I II III
Baculovirus production I III
SeMet labelling III
Chromatographic purifi cation I II III
N-terminal sequencing and mass spectrometry I II III
Crystallization and structure determination III
Immunological methods I II
Antibody production I II
Tissue protein extracts and western blotting I II
Immunohistochemistry I II
Cell culture methods I II III
Primary neuronal cultures I
Transfection I II III
Animal models I II
Rat 6-OHDA model of PD I
Rat model of global forebrain ischemia II
Rat model of status epilepticus II
3.1. DNA and RNA methods
3.1.1. RNA isolation and reverse 
transcription
Human RNAs derived from post-mortem 
brain regions and mouse RNAs were 
isolated with Ambion’s RNAwiz reagent 
(Applied Biosystems). Human RNAs 
of total brain and peripheral tissues 
were purchased from Clontech. First 
strand cDNA synthesis was performed 
with Superscript II reverse transcriptase 
(Invitrogen) as described in (I, II).
3.1.2. PCR, cloning and DNA 
sequencing
RT-PCR analysis of CDNF and MANF 
mRNA expression in human and mouse 
tissues was performed using primers 
listed in Table 4. The PCR programs are 
presented in (I, II). CDNF and MANF 
cDNAs were cloned into pCRII-TOPO 
vector (Invitrogen), verifi ed by sequencing, 
and subcloned into selected expression 
vectors (Tables 5 and 6). 
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Table 4. Primers used for RT-PCR analysis of CDNF and MANF mRNA tissue 
expression.  
Gene Primer Sequence Article
Mouse Cdnf m-Cdnf-ATG 5’-ACCATGCGGTGCATCAGTCCAACTGC-3’ I
Mouse Cdnf m-Cdnf-stop-del 5’-GAGCTCCGTTTGGGGGTATATC-3’ I
Human CDNF h-CDNF-ATG 5’-ACCATGTGGTGCGCGAGCCCAGTTGC-3’ I
Human CDNF h-CDNF-stop-del 5’-GAGCTCTGTTTTGGGGTGTGTC-3’ I
Mouse Manf mManf-ATG 5’-ACCATGTGGGCTACGCGCGGGCT-3’ II
Mouse Manf mManf-stop-del 5’-CAGATCAGTCCGTGCGCTGGCTG-3’ II
Human MANF hMANF-ATG2 5’-ACCATGTGGGCCACGCAGGGGCT-3’ II
Human MANF hMANF-stop-del 5’-CAAATCGGTCGGTGCACTGGCTG-3’ II
Table 5. CDNF and MANF constructs for protein expression. 




EGT signal peptide, Flag, 6His, human 









EGT signal peptide, Flag, 6His, thrombin 
cleavage site, human CDNF aa 1-161 
without endogenous signal peptide
pK503.9 Sf9 III
CDNF-ΔC EGT signal peptide, Flag, 6His, thrombin 
cleavage site, human CDNF aa 1-107 
without endogenous signal peptide
pK503.9 Sf9 III
mCDNF Fusion protein*, 6His, thrombin cleavage 
site, mouse CDNF aa 1-163 without 
endogenous signal peptide, 6His
T7lac based 






hMANF Fusion protein*, 6His, TEV cleavage 
site, human MANF aa 1-158 without 
endogenous signal peptide 




hMANF Fusion protein*, 6His, thrombin cleavage 
site, human MANF aa 1-158 without 
endogenous signal peptide
pHAT based









Honeybee melittin signal peptide, human 





EGT, ecdysone-S-glycotransferase of Autographa californica nuclear polyhedrosis 
virus (AcNPV). TEV, Tobacco Etch Virus. Thrombin cleavage site: LVPRGS; cleavage 
between R-G. *Unpublished (J. Peränen).
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Construct Number Elements of construct Vector Host cell Article
hCDNF-stop E511 human CDNF aa 1-187 pCR3.1 
(Invitrogen)
HEK293T I





mCDNF-V5-His E494 mouse CDNF aa 1-187, V5, 
6His
pcDNA3.1 COS-7 II
hMANF-stop E742 human MANF aa 1-179 pCR3.1 HEK293T II
hMANF-V5-His E443 human MANF aa 1-179, 
V5, 6His
pcDNA3.1 COS-7 II
mMANF-V5-His E444 mouse MANF aa 1-179, 
V5, 6His
pcDNA3.1 COS-7 II
3.1.3. Northern and in situ hybridization
For northern analysis, Manf-specific 
DNA probe was generated with 
Rediprime II system and Redivue dCTP-
32P (Amersham). Hybridization was 
performed on MTN mouse tissue blot 
(BD Biosciences) as described (II). For in 
situ hybridization, probes (Table 7) were 
3.2. Recombinant protein production
3.2.1. CDNF production, purifi cation 
and SeMet labelling
Recombinant baculoviruses encoding 
human CDNF (I) or the N-terminal 
domain of CDNF (CDNF-ΔC; III) 
were produced according to Bac-to-Bac 
protocol (Gibco-BRL). Protein expression 
of each baculoviral stock was tested and 
optimized in Sf9 Lepidopteran cells by 
varying the amount virus stock used for 
the infection and the infection time. 
CDNF was purifi ed from cleared Sf9 
culture supernatants at three days post-
infection as described in detail (I, III). 
Briefly, CDNF-containing supernatant 
(adjusted at pH 7.5) was incubated 
batchwise with nickel-charged chelating 
sepharose (Amersham). After washing 
with 0.5M NaCl, CDNF was eluted with 
0.5 M imidazole, pH 8.0, and concentrated. 
Subsequently, CDNF was applied to 
synthesized by in vitro transcription using 
35S-labelled UTP (Amersham) as described 
(I, II). Hybridization temperature was 
52 ºC. Washing was performed at 55 ºC 
or at 65 ºC for Cdnf or Manf, respectively. 
Hybridized sections were exposed in 
NTB2 emulsion (Kodak) for 5-6 weeks 
(Cdnf) or 5 days (Manf) (I, II). 
Table 7. Probes for in situ and northern hybridization.
Probe GenBank 
Accession No.
Nucleotides Length Vector Construct No. Article
Mouse Cdnf* NM_177647 63-623 561 bp pCRII E496 unpublished
Mouse Cdnf-P* NM_177647 409-823 414 bp pCRII E753 I
Mouse Manf NM_029103 41-577 536 bp pCRII E509 II
 *Only for in situ hybridization.
Materials and methods
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anion exchange chromatography HiTrap 
Q HP column (Amersham) and eluted 
with 0-1 M NaCl gradient at pH 8.2. For 
crystallization and structure determination, 
CDNF proteolytic fragment (CDNF-
ΔC) that co-purified with full-length 
CDNF, was purified with gel filtration 
(III). Baculovirally expressed CDNF-ΔC 
was labelled with selenium-methionine 
(SeMet), purified and crystallized as 
described in (III). Constructs used for 
CDNF production are listed in Table 5, 
and recombinant proteins are presented 
schematically in Fig. 6A.
3.2.2. MANF production and 
purifi cation
Recombinant human MANF was produced 
in E.coli and purifi ed as described (I, II, 
III). In addition, a stable Sf9 cell line 
expressing recombinant human MANF 
was created, and MANF was purifi ed from 
culture supernatant as described in (II). 
Constructs used are listed in Table 5, and 
recombinant MANF proteins are presented 
schematically in Fig. 6B.
Figure 6. Schematic presentation of recombinant CDNF (A) and MANF (B) proteins. Mature 
CDNF or MANF is indicated in white; tags and additional residues in grey. Relative numbers of 
amino acids are shown. Proteins are presented from N to C terminus. 
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3.2.3. N-terminal sequencing and mass 
spectrometry
Amino-terminal sequence analysis 
was performed with Procise 494A 
Sequencer (Perkin Elmer), and Q-TOF 
instrumet (Micromass Ltd.) was used for 
electrospray mass spectrometry (I, II, III). 
Peptide mass fi ngerprints were analyzed 
with Ultrafl ex TOF/TOF (Bruker Daltonik 
GmbH) matrix-assisted laser desorbtion/
ionization time-of-fl ight (MALDI-TOF) 
mass spectrometer (I, II). 
3.2.4. Crystallization and structure 
determination
Sitting-drop vapour-diffusion technique of 
Helsinki robot crystallization facility was 
used to screen crystallization conditions 
for CDNF-ΔC, SeMet substituted CDNF-
ΔC and full-length MANF as described 
in (III).  Data for structural determination 
was collected at European Synchrotron 




Recombinant mouse CDNF or human 
MANF proteins produced in E.coli were 
used for the immunization of rabbits as 
described (I, II). Antisera were affinity 
purified by using CDNF or MANF 
coupled to cyanogen bromide sepharose 
(Amersham) beads (I, II). Antibody 
specificity was tested by preincubating 
the antibody with recombinant CDNF 
or MANF before application on western 
blotting or immunohistochemistry (I, II). 
3.3.2. Tissue protein extracts and 
western blotting
Total post-nuclear proteins from freshly 
frozen mouse tissues were extracted in 
high salt-high detergent lysis buffer as 
described (I, II). Proteins were detected in 
the western blots using ECLTM detection 
reagents (Amersham) (I, II). Antibodies 
used are listed in Table 8.
3.3.3. Immunohistochemistry
Tissue processing and immunohisto-
chemistry was performed as described (I, 
II). Antibodies used are listed in Table 8. 
 3.4. Cell culture methods
3.4.1. Primary neuronal cultures
Cultures for mouse P1 superior cervical 
ganglion (SCG) sympathetic neurons, 
mouse E14 or E15 dorsal root ganglion 
(DRG) sensory neurons and rat E14 
Table 8. Primary antibodies used for western blotting and IHC.
Antibody Host Source/Manufacturer Dilution Article
CDNF Rabbit Saarma group 1:750*
1:40**
I II
MANF Rabbit Saarma group 1:1000*
1:100**
I II
TH Mouse MAB318, Chemicon 1:2000** I II
Actin Mouse AC-40, Sigma 1:1000* I II
NeuN Mouse MAB377, Chemicon 1:500** I II
* Used in Western blotting; ** used in IHC.
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motoneurons were established as described 
(I).
3.4.2. Transfection
Transfection of CDNF and MANF 
vectors into different mammalian cell 
lines with Lipofectamine 2000 reagent 
(Invitrogen) was performed according 
to the manufacturer’s instructions (I, II). 
Mammalian expression vectors encoding 
CDNF or MANF are listed in Table 6. 
3.5. Animal models
3.5.1. 6-OHDA rat model of Parkinson’s 
disease
Activity of recombinant CDNF was tested 
in a partial rat 6-OHDA model of PD (I). 
Experimental setup for the neuroprotection 
and neurorestoration experiments, 
respectively, is presented in Fig. 7. 
3.5.2. Rat model of global forebrain 
ischemia or status epilepticus
Ischemia was induced with bilateral 
occlusion of common carotid arteries 
combined with hypotension. Circulation 
was restored after 10 min by blood 
reinfusion and removal of occlusion clasps 
(II). Status epilepticus (SE) was induced 
electrically as described (II). Animals were 
decapitated at 2h, 24h and 1 week after the 
reinfusion (ischemia) or the end of SE.  
Figure 7. Experimental setup for neuroprotection (A) and neurorestoration (B) studies in a 
6-OHDA model of PD.
Materials and methods
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4.1. CDNF is a vertebrate paralogue of 
MANF (I)
Bioinformatic search retrieved partial 
human and mouse expressed sequence tag 
(EST) sequences homologous to MANF 
(ARMET) cDNA. These cDNAs encoded 
4. RESULTS
previously unknown protein of 187 amino 
acids (Fig. 8A, B), which we named as 
conserved dopamine neurotrophic factor, 
CDNF. We amplifi ed CDNF cDNA from 
human and mouse tissues by RT-PCR. In 
public databases, CDNF is also referred 
as ARMET-like 1 (ARMETL1). However, 
Figure 8. A) Alignment of CDNF and MANF amino acid sequences from selected organisms. 
Signal peptides are underlined and conserved cyteines boxed. N-linked glycosylation site in hu-
man CDNF is indicated in red and putative ER-retention signals in blue. B) Schematic presenta-
tion of CDNF and MANF proteins from human, fl y and worm. Percent of identical amino acids 




the name ARMET is misleading, since only 
human MANF but not genes homologous 
to human CDNF or MANF from other 
species contains an amino-terminal 
arginine-rich region. Furthermore, the 
arginine-rich region of human MANF is 
apparently not translated in vivo (Petrova 
et al. 2003).
CDNF and MANF encoding genes are 
highly conserved in evolution. Analyses of 
EST and genomic sequences of different 
organisms suggest that vertebrates 
have CDNF and MANF genes, whereas 
invertebrates, including C. elegans and D. 
melanogaster, have a single homologous 
CDNF/MANF gene. Characteristic feature 
of CDNF and MANF proteins is eight 
cystine residues, spacing of which is 
conserved (Fig. 8A, B). 
4.2. CDNF and MANF are secreted 
proteins (I, II) 
Transiently overexpressed human CDNF 
and MANF proteins were efficiently 
secreted from mammalian cells (I, II). 
Similar results were obtained with mouse 
CDNF and MANF proteins (data not 
shown). The signal peptide of native 
human CDNF or MANF was cleaved 
after residue 26 (glycine) or 21 (alanine), 
respectively, resulting mature protein 
of 161 (I) and 158 amino acids (II) (Fig. 
8B). CDNF and MANF proteins seem not 
to contain pro-sequence, suggesting that 
enzymatic cleavage is not necessary for 
their activity (I, II). 
The amino acid sequence of human 
CDNF contains one potential N-linked 
glycosylation site, whereas mouse CDNF 
or MANF, or human MANF sequences 
do not contain potential N- or O-linked 
(serine/threonine-linked) glycosylation 
sites. Based on ESI-MS analysis, 
recombinant human CDNF-V5-6His and 
MANF-V5-6His proteins secreted from 
COS-7 cells were not glycosylated or post-
translationally modifi ed (I, II). 
4.3. Protein production and 
purifi cation (I, II, III)
Recombinant Flag-6His-hCDNF produced 
by baculoviral expression in insect cells 
was purifi ed to an estimated fi nal purity 
of ~90% (I). Based on ESI-MS, Flag-
6His-hCDNF was not post-translationally 
modified (I). This CDNF protein was 
used in the 6-OHDA model of PD (I). 
Schematic presentation of recombinant 
CDNF proteins expressed by baculovirus 
in Sf9 cells, and MANF proteins expressed 
in a stable Sf9 cell line or in E.coli is 
shown in Materials and Methods (Fig. 6). 
S ince  the  c rys ta l l i za t ion  of 
recombinant mature Flag-6His-hCDNF 
failed due to its high solubility, and 
production trials of mature CDNF using 
E.coli expression system gave partially 
degraded CDNF and low protein yields 
(data not shown), we decided to crystallize 
a proteolytic fragment of CDNF (CDNF-
ΔC; aa 1-107) which was identifi ed in the 
baculoviral cultures of Flag-6His-hCDNF 
(III). SeMet-labelled CDNF-ΔC fragment 
was produced using baculoviral expression 
in insect cells, purified and crystallized 
(III).
Mature human MANF was expressed 
in E.coli, purifi ed (II) and crystallized (III). 
Also human MANF-V5-6His produced 
in a stable Sf9 cell line was successfully 
purifi ed (II). Human CDNF and MANF 
proteins produced in insect cells were 
detected exclusively as monomers when 
analysed in non-denaturating SDS-
polyacrylamide gel electrophoresis (SDS-




4.4. Crystal structure of CDNF and 
MANF (III)
The crystal structure of N-terminal domain 
of CDNF (CDNF-ΔC) was solved from a 
crystal of SeMet-substituted protein at 
resolution of 1.6Å (Fig. 9B). The structure 
model consists of residues 9-105 of the 
mature CDNF in two chains. CDNF-
ΔC contains fi ve α-helices followed by a 
turn of 310 helix, which form a globular, 
saposin-like “closed” conformation. The 
saposin-like fold is stabilized by three 
intramolecular disulphide bonds, which 
connect α1 and the C-terminal 310 helix, α1 
and α5 helix, α2 and α3 helix, respectively 
(Fig. 9A).
The structure of human MANF 
(residues 1-137 of mature protein) was 
resolved by molecular replacement 
using the structure of CDNF-ΔC, and 
was refined at resolution of 2.8Å (Fig. 
9D). Residues 138-158 are not visible 
in the structure. The N-terminal domain 
of MANF is saposin-like and essentially 
similar to that of CDNF. The C-terminus 
of MANF appears to be natively unfolded. 
It contains a loop region (residues 95-
111) followed by two parallel α-helices 
α6 and α7, which are connected with 
a loop formed by residues 123-130. 
MANF C-terminus contains one CXXC 
motif (127CKGC130), which forms an 
internal disulphide bond. Presumably the 
C-terminal structure of CDNF is similar to 
that of MANF, and contains a disulphide 
bridge in the 132CRAC135 motif. 
The closest structural homologs for 
CDNF-ΔC and the N-terminal domain 
of MANF are saposin-like proteins 
(SAPLIPs) granulysin (Fig. 9C) (Anderson 
et al. 2003) and NK-lysin (Fig. 9E) 
(Liepinsh et al. 1997). 
4.5. CDNF expression in mammalian 
CNS (I) 
Cdnf transcripts were detected by RT-
PCR in the developing embryonic (E12-
E18) and postnatal (P1, P4, P7, P14) 
mouse brain, and in all adult mouse and 
adult human brain regions analyzed. 
CDNF mRNA was detected in the caudate 
nucleus and putamen (striatum) and SN of 
adult human and mouse, and in the mouse 
embryonic (E13, E18) and postnatal (P1, 
P10) midbrain (I). 
In situ hybridization analysis of 
Cdnf mRNA expression was performed 
with two Cdnf cRNA probes (414 bp 
and 561 bp; see Materials and Methods). 
We used low stringency washing for 
Cdnf, since high stringency used in Manf 
detection protocol gave no signal with the 
Cdnf cRNA probe (561 bp) tested. Cdnf 
cRNA probe (414 bp) gave a specific 
although weak hybridization signal in 
several brain regions of P1 and P10 
mouse brain, in line with the results of 
CDNF immunohistochemical analysis (I). 
Relatively high Cdnf-specifi c signal was 
detected in the hippocampus and thalamus 
of P1 and P10 mouse brain, and in the 
olfactory bulb of P1 mouse (I). With the 
full-length Cdnf probe (561 bp), a specifi c 
hybridization signal was detected only in 
the thalamus of P10 mouse brain (data not 
shown), but not in any other brain regions 
at P10, or in brain sections from other 
developmental stages analyzed (P1, P5 or 
adult; data not shown). 
Consistently with the obtained ISH 
data, immunohistochemical analysis 
indicated widespread expression of 
CDNF protein in P1, P10 and adult 
mouse brain. In the adult cerebral cortex, 
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Figure 9. A) Alignment of saposin domains of CDNF and MANF, granulysin (Swiss-Prot 
P22749; residues 62-142) and NK-lysin (Swiss-Prot Q29075; residues 46-126). Six* conserved 
cysteines are boxed, and intramolecular cysteine bridges are indicated below the alignment. 
Helical regions of CDNF and MANF are shown above the sequences. Hs, human; Dm, fruitfl y; 
Ce, roundworm; Ss, pig. *Granulysin contains fi ve cysteines and two intramolecular disulphide 
bridges. CDNF saposin domain (B) and granulysin (C) in a closed conformation. D) Crystal 
structure of MANF. The C-terminal cysteine bridge in a CXXC motif indicated with an arrow. E) 
Overlay of MANF saposin-domain and NK-lysin.
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CDNF labelling co-localized with 
NeuN, indicating neuronal expression of 
CDNF. In the SN, CDNF labelling did 
not co-localize with TH suggesting that 
CDNF is not expressed in dopaminergic 
neurons. Locus coeruleus, which contains 
noradrenergic neurons, stained positive 
for CDNF (I). We were unable to detect 
CDNF signal in embryonic mouse CNS 
by IHC. 
The expression analysis of CDNF on 
tissue sections by ISH and IHC techniques 
was difficult since both methods gave 
only weak specifi c signals, suggesting that 
Cdnf mRNA and protein were expressed 
at low levels in mouse tissues. In contrast, 
the expression of Manf mRNA and 
protein was easy to detect using ISH and 
IHC methods suggesting higher levels 
of expression as compared to those of 
CDNF. To evaluate antibody specifi city, 
we pre-incubated anti-CDNF and anti-
MANF antibodies with recombinant 
CDNF or MANF proteins before applying 
them on tissue sections (I, II). Although 
this control suggested specifi city for the 
both antibodies, it is important to test the 
antiboodies on tissue samples derived 
from CDNF or MANF knockout mice to 
further evaluate their specifi city, and the 
accuracy of obtained expression data. This 
work is currently ongoing. 
4.6. MANF expression in mammalian 
CNS (II)
Based on RT-PCR analysis, Manf had a 
wide expression pattern in the brain, thus 
resembling that of Cdnf. Manf transcripts 
were detected in the embryonic (E13, 
E15), postnatal (P9, P14) and adult (P60) 
mouse brain and in all human brain regions 
analyzed, including the SN, caudate 
nucleus and putamen (II). 
Consistently, in situ hybridization 
analysis indicated widespread Manf mRNA 
expression in several brain regions of P1, 
P10 and adult mouse brain. Manf signal 
was relatively abundant in the cerebral 
cortex, hippocampus, and cerebellar 
Purkinje cells of adult mouse, and it was 
also detected in the striatum and SN. In 
the brain, Manf signal localized mainly in 
cells with large nuclei, suggesting neuronal 
expression. High levels of Manf mRNA 
were also detected in the non-neuronal 
cells of choroid plexus. 
Results from the IHC analysis of 
MANF protein expression were consistent 
with the results obtained from in situ 
hybridization analysis. MANF protein 
was detected in the cerebral cortex, 
hippocampus and cerebellar Purkinje cells 
of adult mouse. It was also detected in the 
striatum and substantia nigra of P1, P10 
and adult mouse. In the adult SN, MANF 
was detected in TH positive neurons.  
Also the in situ hybridization and 
immunohistochemical analyses of 
embryonic tissues gave consistent results. 
Manf mRNA and protein were expressed 
at high levels in the developing cerebral 
cortex of E12.5 and E14 mouse embryos, 
respectively. MANF protein was also 
detected in the developing midbrain of 
E16 mouse embryos, although at low 
level. MANF protein was localized in 
embryonic PNS, including dorsal root, 
trigeminal and superior cervical ganglia of 
E17 mouse embryos. 
4.7. MANF expression after epileptic 
and ischemic insults (II)
Manf mRNA expression was signifi cantly 
increased 2h after SE in the hippocampal 
dentate granule cell layer (to 171% 
of control), in the thalamic reticular 
nucleus (to 170% of control) and in the 
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retrosplenial cortex (to 175% of control). 
After 24h, expression had increased in the 
piriform and parietal cortical areas (to 175 
and 136% of control, respectively). The 
increase in Manf expression was transient, 
and not detectable 1 week after SE. 
After global forebrain ischemia, 
Manf mRNA levels were increased mainly 
in the hippocampal formation. Transient 
increase of Manf mRNA transcripts 
was detected in the granule cell layer 
of dentate gyrus, in hilus and in the 
CA1 region (to 157, 137, and 151% of 
control, respectively). Increase of Manf 
mRNA levels were detected also in the 
retrosplenial cortex (to 136% of control) 
2h after the insult. However, no changes 
were detected in other cortical areas or in 
thalamic reticular nucleus. The increase 
in Manf expression was transient, and 
not detected 1 week after ischemia. After 
both insults, Manf expression was mostly 
neuronal in all examined structures. 
4.8. CDNF and MANF expression in 
non-neuronal tissues (I, II)
Based on RT-PCR analysis, CDNF mRNA 
was expressed in several non-neuronal 
tissues of adult human and mouse. 
Relatively high levels of CDNF transcripts 
were detected in the skeletal muscle and 
testis of human and mouse, and in the 
mouse heart (I). Consistently, western blot 
analysis indicated high levels of CDNF 
protein in the heart, skeletal muscle and 
testis (I). High CDNF protein levels were 
detected also in the seminiferous tubules 
and skeletal muscle of adult mouse by 
IHC (data not shown). 
RT-PCR and northern blot analyses 
revealed high Manf expression in the liver 
and testis of adult mouse, in contrast to 
skeletal muscle, in which Manf expression 
was relatively low (II). The results were 
in line with the western blot analysis 
of MANF protein expression in adult 
mouse tissues. Based on the ISH and IHC 
analyses, MANF expression was abundant 
in the seminiferous tubules of adult mouse, 
especially in the early spermatocytes (II). 
Consistently with the expression data 
obtained from mouse, MANF was widely 
expressed in non-neuronal tissues of adult 
human (II).
In situ hybridization analysis of 
embryonic mouse tissues revealed high 
Manf levels in the E12.5 mouse liver, 
cartilage primordia of head and vertebra, 
and umbilical vessels (II). Consistent 
results were obtained from analysis of E15 
mouse embryos (data not shown). MANF 
expression was high in many secretory 
tissues. Robust MANF expression was 
detected in the salivary gland of E17 
mouse embryos by ISH and IHC, and in 
pancreas by IHC (II).  
4.9. Neuroprotective effect of CDNF in 
6-OHDA rat model of PD (I)
In the neuroprotection studies, CDNF 
(10 μg) injected into the striatum 6h 
before intrastriatally injected 6-OHDA 
significantly reduced amphetamine-
induced rotational behaviour at two (P 
< 0.01) and at four weeks (P < 0.05) 
post-lesion. Consistently, the number of 
dopaminergic TH-positive cells in the 
SNpc and density of TH-positive fibers 
in the striatum were signifi cantly higher 
in CDNF-treated rats (96% of the intact 
side, P < 0.001 for TH-positive cells; 
75% of the intact side, P < 0.001 for 
TH-positive fibers) as compared to the 
vehicle-treated rats (65% for TH-positive 
cells and 55% for TH-positive fibers). 
The neuroprotective effect of CDNF was 
similar to that of GDNF. GDNF (10 μg) 
injection before 6-OHDA significantly 
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reduced the rotational behaviour at two 
(P < 0.01), but not at four weeks post-
lesion and increased the number of nigral 
TH-positive cells (93% of the intact side, 
P < 0.001) and the density of striatal TH-
positive fibers (69%, P < 0.01) at four 
weeks post-lesion.  The neuroprotective 
effect of CDNF was dose-dependent: 
at 3 μg CDNF signifi cantly reduced the 
rotational behaviour and the increased 
number of TH-positive cells in the SNpc, 
but less efficiently than at the dose of 
10 μg. The protective effect of CDNF 
at the dose of 1 μg was not statistically 
signifi cant.     
4.10. Neurorestorative effect of CDNF 
in 6-OHDA rat model of PD (I)
In the neurorestoration studies, CDNF 
(10 μg) injection into the striatum four 
weeks after striatal 6-OHDA injection 
was able to restore the functional activity 
of nigrostriatal dopaminergic system in 
adult rats. The amphetamine-induced 
rotational behaviour of CDNF-treated rats 
was signifi cantly reduced 8 weeks after 
the protein injection (i.e. 12 weeks after 
the 6-OHDA injection), as compared with 
the vehicle-treated control group. The 
neurorestorative effect of GDNF (10 μg) 
was similar to that of CDNF at 12 weeks 
post-lesion. In line with the behavioural 
studies, the number of TH-positive cells in 
the SNpc was higher in the CDNF-treated 
rats (58% of the intact side, P = 0.0629), 
and in the GDNF-treated rats (57%, P < 
0.05) as compared to the vehicle-treated 
rats (26% of the intact side). 
4.11. Studies on the survival promoting 
activity of CDNF on primary neuronal 
cultures (I)
CDNF (100 ng/ml) did not promote the 
survival of P1 mouse superior cervical 
ganglion (SCG) sympathetic neurons or 
E14 and E15 mouse dorsal root ganglion 
(DRG) sensory neurons in culture. CDNF 
(0.1-100 ng/ml) had no effect on the 






5.1. A possible dual role of CDNF and 
MANF
In the present study we identified and 
characterized CDNF (I, III), a novel 
vertebrate protein homologous to MANF 
(Petrova et al. 2003). CDNF and MANF 
form a novel protein family conserved 
from humans to invertebrates, including 
C. elegans and D. melanogaster. Recent 
evidence by us and others suggest a dual 
role for these proteins as extracellular 
neurotrophic factors and as ER resident 
cytoprotective proteins. CDNF (I) and 
MANF (Petrova et al. 2003; Voutilainen 
et al. submitted) promote the survival 
of midbrain dopaminergic neurons, and 
MANF is also cytoprotective against ER 
stress induced cell death (Apostolou et 
al. 2008; Tadimalla et al. 2008). CDNF 
and MANF have widespread expression 
in mammalian tissues (I, II) suggesting 
that they affect many cell types. We have 
resolved the crystal structure of MANF 
and CDNF, which will help to reveal the 
action mechanisms of these new proteins 
at molecular level (III).
5.1.1. Secretion and ER localization of 
CDNF and MANF 
In line with the observed neurotrophic 
activities, CDNF and MANF are secreted 
proteins. We showed that CDNF and 
MANF are secreted from transiently 
transfected cells (I, II), and a recent study 
presented consistent results (Apostolou 
et al. 2008). Importantly, the authors also 
show that endogenous MANF is secreted 
from human cervical cancer HeLa cells 
(Apostolou et al. 2008). CDNF and MANF 
are highly soluble and monomeric at 
neutral pH 7 (data not shown) (Mizobuchi 
et al. 2007). Based on mass analysis, 
human CDNF secreted from transiently 
transfected mammalian cell lines was not 
glycosylated (I). Human CDNF contains 
a potential N-linked glycosylation site in 
the saposin-like domain (Fig. 8A), and 
others have shown that a glycosylated 
form of human CDNF is also secreted 
from transiently overexpressing cells 
(Apostolou et al. 2008). However, we 
have shown that unglycosylated CDNF 
is biologically active (I), indicating 
that glycosylation is not crucial for its 
activity. Mouse CDNF, or human and 
mouse MANF do not have potential N- 
or O-linked glycosylation sites. MANF 
secreted from transiently transfected cells 
was not glycosylated (II), in line with the 
study by Apostolou et al. (2008), and in 
contrast to the original report (Petrova 
et al. 2003) which introduced MANF as 
a silalylated protein. The reason for this 
discrepancy is unclear. Many SAPLIPs are 
glycoslated, but the glycosylation has not 
been related to their activity, suggesting 
that it regulates protein stability or 
lifetime (Bruhn 2005). Neurotrophic 
factor GDNF has two glycosylation sites, 
but unglycosylated recombinant GDNF 
is biologically active (Lin et al. 1994), 
although the glycosylated forms are more 
stable and thus more potent in inducing 
tyrosine phosphorylation of RET in vitro 
(Mart Saarma, personal communication). 
In line with the role of MANF in 
ER stress, MANF also localizes in the 
ER (Apostolou et al. 2008; Mizobuchi 
et al. 2007). MANF and CDNF have a 
C-terminal sequence (RTDL and KTEL, 
respectively) closely resembling the 
classical ER retention signal (KDEL) 
(Fig. 8A). This sequence may function as 
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a partial ER retention signal (Apostolou et 
al. 2008; Raykhel et al. 2007). 
Whether the secretion of endogenous 
CDNF or MANF is regulated by 
physiological stimuli or injury is unclear. 
ER stress had only a minor effect on the 
secretion of MANF and CDNF from 
transiently transfected cells (Apostolou et 
al. 2008), suggesting a cell-autonomous 
role in the ER stress. 
5.1.2. CDNF and MANF: Lipid binding 
proteins?
Analysis of the crystal structure shows 
that CDNF and MANF consist of two 
domains: the saposin-like N-terminal 
domain with fi ve α-helices stabilized by 
three disulphide bridges, and presumably 
unstructured C-terminal domain with a 
disulphide bridge in a CXXC motif (III) 
(Fig. 9B, D). 
Characteristic feature of saposin-like 
proteins is their ability to interact with 
membranes or lipids (Bruhn 2005). The 
closest structural homologues of human 
CDNF and MANF N-terminal domain 
are SAPLIPs granulysin (Anderson et al. 
2003) and NK-lysin (Liepinsh et al. 1997) 
which function as defence proteins against 
bacterial cells (Andersson et al. 1995; Peña 
et al. 1997; Jongstra et al. 1987). They are 
able to disrupt a target cell membrane and 
increase its permeability. Granulysin and 
NK-lysin are proteolytically processed in 
cytolytic granules from pro-polypeptides. 
Activity of granulysin is decreased in the 
acidic environment of cytolytic granules, 
which is to protect the cell from damage 
(Hanson et al. 1999). In contrast, CDNF 
and MANF are likely functional upon 
synthesis and secretion; they do not seem 
to contain pro-sequences for enzymatic 
activation (I, II). However, whether they 
are proteolytically cleaved remains open.  
The fi rst obvious question based on 
the structural data is whether CDNF and 
MANF interact with lipids or membranes. 
Our recent studies indicate that they do 
(Hongxia Zhao and Mart Saarma, personal 
communication). Indeed, lipid interaction 
may be crucial for the activity of CDNF 
and MANF proteins. 
5.1.3. The putative membrane 
interaction of CDNF and MANF: 
Dimerization, conformational changes 
and pH effect? 
Molecular mechanisms of lipid and 
membrane interactions of saposins, NK-
lysin and granulysin have only partially 
been revealed. Characteristic features of 
the membrane interactions of SAPLIPs 
are oligomerization and conformational 
changes in the saposin fold. Composition 
of membrane lipids and pH are known to 
affect membrane binding of SAPLIPs.
Charge distribution on the surface of 
SAPLIPs may have an important role in the 
membrane targeting. NK-lysin (Liepinsh 
et al. 1997) and granulysin (Anderson et 
al. 2003) have a ring of positively charged 
residues around the molecule, which 
may direct their interaction towards the 
negatively charged lipid head groups in 
the membrane. The saposin-like domain 
of CDNF and MANF has conserved 
positively charged residues on the surface 
in two patches; in MANF, one patch is 
formed by residues R44, K46, R49 and 
K96, the other by residues K70, K80, 
K84, K86 and K87, respectively. These 
residues may contribute to the membrane 
interactions (III). 
Oligomerization facilitates the 
membrane interaction of many SAPLIPs. 
Amoebapores form oligomers on a target 
cell membrane that are necessary for pore 
formation and subsequent lysis (Zhai and 
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Saier 2000). Consistently, cooperation 
between granulysin monomers may 
induce membrane disruption (Anderson 
et al. 2003). Interestingly, the saposin-like 
domain of CDNF crystallized as a dimer 
at pH 4.6, whereas the full-length, mature 
MANF crystallized as a monomer at 
neutral pH (III). Whether the dimerization 
of CDNF (or MANF) at low pH is 
biologically relevant is currently unknown. 
Structurally unrelated neurotrophic 
factors, GFLs and neurotrophins, function 
as homodimers showing that dimerization 
is a common theme in the function of 
neurotrophic factors.  
Conformational changes in the 
saposin-like domain seem to regulate the 
membrane/lipid interactions and biological 
activities of SAPLIPs. Hydrophobic 
residues located at conserved positions 
are buried in the domain interior, forming 
a hydrophobic core, which may have a 
role in the lipid interactions of SAPLIPs 
(Bruhn 2005). In the crystals, the saposin-
like domain of CDNF and MANF was in 
a globular, compact conformation, with 
a relatively small hydrophobic core (III). 
In this conformation, two “leafs” (Bruhn 
2005), one formed by helices α1, α2, 
and α3; and the other formed by helices 
α4 and α5, are closed together (III). 
Conformational changes of SAPLIPs have 
been reported in the presence of detergents 
and in response to pH changes. Whether 
conformational changes in the SAPLIP 
domain facilitate the lipid interactions of 
CDNF and MANF will be revealed by 
future studies. 
SapB, a protein with lipid transfer 
activity (Vogel et al. 1991), crystallized as 
a homodimer, in which the two monomers 
had adopted an open conformation thus 
facilitating lipid access to the hydrophobic 
cavity (Fig. 5C) (Ahn et al. 2003). In the 
presence of detergent, SapC monomer 
crystallized in an open conformation with 
a solvent-exposed hydrophobic pocket, 
which is likely to contact with membrane 
lipids (Hawkins et al. 2005). Also at pH 4, 
SapC crystallized in an open conformation, 
but as a domain-swapped dimer (Fig. 
5D). This conformation of SapC may 
facilitate vesicle fusion (Rossmann et al. 
2008). SapC and SapA form oligomers 
in the presence of a detergent at low pH 
4.8 (Ahn et al. 2006). Thus, the lysosomal 
lipid-rich acidic environment may induce 
conformational changes in SapC and SapA 
that are needed for their activities (Ahn et 
al. 2006). In line, acidic pH also increases 
the ability of SapC and SapD to bind lipid 
vesicles and destabilize phospholipid-
containing membranes (Vaccaro et al. 
1995). Differently from saposins, which 
are acidic molecules with pI values 
4.6 - 4.8, CDNF and MANF saposin-
like proteins are slightly basic with pI 
values 7.7 and 8.6, respectively. Whether 
pH affects the membrane interactions of 
CDNF and MANF will be studied in the 
future. 
The role of lipids and membrane 
interactions in the biology of CDNF and 
MANF are currently unknown. Does lipid 
binding induce dimerization of CDNF 
and MANF and subsequent activation? 
The mechanism of CDNF and MANF 
membrane/lipid interaction is not known. 
However, it does not seem likely that 
CDNF and MANF disrupt the target 
membranes like granulysin and NK-lysin, 
since we have not observed cell death 
induced by CDNF or MANF. Whether 
CDNF and MANF have lipid transfer 
properties similar with those of saposins is 
not known. Hypothetical modes of CDNF 
and MANF dimerization and membrane 
interaction are presented in Fig. 10. 
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Figure 10. Hypothetical modes for CDNF (and MANF) action. A) Change in pH or lipid binding 
may trigger CDNF dimerization. B) CDNF may facilitate the correct formation of disulphide 
bonds on secretory proteins in the ER.  –SH; thiol group; -S-S-, cysteine bond. C) The cysteine 
bridge in a CXXC motif may be redox active also on the cell surface. D) CDNF binding to 
membrane may lead to the activation of transmembrane protein receptor and subsequent 
intracellular signalling. Saposin-domain (N) and C-terminal domain (C) of CDNF is connected 
by a fl exible linker region.  
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5.1.4. The C-terminal domain: 
Cytoprotection against ER stress?  
In the MANF C-terminal–domain the 
two cysteines in 127CKGC130 motif 
(132CRAC135 in CDNF) form a C-terminal 
diulphide bridge (III). The C-terminal 
domain is presumably natively unfolded; 
the conformation seen in the crystal 
is stabilized by crystal contacts and 
apparently is one out of several possible 
conformations. 
Interestingly, a CXXC active site motif 
is found in thiol/disulfi de oxidoreductases 
which catalyze the formation of 
intramolecular disulphide bonds. These 
proteins include thioredoxins, like protein 
disulphide isomerases (PDIs), which 
function in the ER (Ellgaard and Ruddock 
2005). The CXXC motif functions in 
reduction, oxidation and isomerisation 
reactions that are necessary for proper 
disulphide bond formation of target 
proteins in the ER (Horibe et al. 2004). 
The CXXC motif may also bind metal 
ions in metal-binding proteins, including 
PDI (Narindrasorasak et al. 2003). It has 
been shown that nitrosylation of the PDI 
active site motif inhibits activity of PDI, 
induces intracellular accumulation of 
polyubiquitinated proteins and cell death 
in vitro. Furthermore, nitrosylated PDI is 
found in brain samples derived from PD 
patients, indicating a link between PDI 
dysfunction and protein misfolding in 
neurodegenerative disorders (Uehara et al. 
2006). 
Oxidoreducatases are also secreted 
and they may be cell surface-associated 
(Jordan and Gibbins 2006). Interestingly, 
evidence suggests that the reduction and 
rearrangement of disulphide bonds is a 
mechanism of controlling protein function 
on the cell surface (Hogg 2003). Cell 
adhesion, uptake of bacterial toxins and 
viral fusion with a host cell membrane 
may depend on thiol-disuphide exchange 
reactions (Hogg 2003). Extracellular redox 
catalysts have been shown to regulate the 
functional forms of cell surface proteins as 
well as receptor-ligand interactions. For 
example, thioredoxin 1 (TRX1) mediates 
disulphide reduction in CD30 (tumor 
necrosis factor receptor superfamily 
member 8; TNFRS8), which induces a 
subsequent conformational change and 
affects functional properties of the CD30 
ectodomain, thus regulating infl ammatory 
response (Schwertassek et al. 2007). 
Extracellular TRX also activates TRPC5 
(transient receptor potential, canonical 5) 
ion-channel located on the cell surface 
by breaking a disulphide bridge (Xu et 
al. 2008).  Extracellular PDI is known to 
mediate entry of human immunodefi ciency 
virus 1 (HIV-1) into lymphoid cells by 
catalysing redox changes of the HIV-1 
envelope glycoprotein gp120 (Hogg 
2003). 
Recent studies have revealed that 
MANF (and presumably also CDNF) is 
cytoprotective against ER stress induced 
cell death (Apostolou et al. 2008; 
Tadimalla et al. 2008). Accumulation 
of unfolded proteins in the ER induces 
UPR, a signal-transduction pathway to 
counteract ER stress (Fig. 4) (Szegezdi 
et al. 2006b). If the ER stress is severe, 
apoptotic signalling is activated, leading 
to cell death. Inhibition of MANF 
expression by RNA interference (RNAi) 
increased tunicamycin-induced cell death 
and expression of UPR factors in HeLa 
cells (Apostolou et al. 2008). The crystal 
structure of MANF C-terminal domain 
supports the idea of MANF (and CDNF) 
as an “anti-ER stress” protein. MANF 
and CDNF may facilitate the formation 
of cysteine bridges and protein folding in 
the ER, thus reducing the ER stress caused 
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by unfolded or incorrectly folded proteins 
(III) (Fig. 10B). 
The studies of Apostolou et al. (2008) 
and Tadimalla et al. (2008) were based 
on earlier reports showing Armet (Manf) 
upregulation in ER stress conditions 
(Holtz et al. 2005; Lee et al. 2003; 
Belmont et al. 2008; Mizobuchi et al. 
2007). We found transient upregulation 
of Manf mRNA in adult rat brain after 
two pathological conditions, SE and 
global forebrain ischemia, suggesting that 
MANF may regulate neuronal survival 
and synaptic plasticity (II). In line with 
our data, ARMET protein was upregulated 
in cortical neurons after cortical ischemia 
induced by MCAO in rats (Apostolou 
et al. 2008). Whether the expression of 
Cdnf mRNA is regulated in SE or global 
forebrain ischemia is currently unknown. 
In contrast to Manf, Cdnf (Armetl1) 
expression was not upregulated by ER-
stressors in vitro, suggesting that CDNF 
acts constitutively in the ER (Apostolou 
et al. 2008). However, the role of CDNF 
in the ER stress response needs further 
studies. 
Interesting question is whether 
MANF and CDNF have oxidoreductase 
or metal binding activities, and if they 
do, what are the target molecules. Could 
cell-surface bound extracellular MANF or 
CDNF regulate disulphide bond breakage 
or formation on cell-surface proteins, 
including cell surface receptors (Fig. 
10C)? Although the initial experiments 
did not detect oxidoreductase activity or 
bound metal ions in MANF (Mizobuchi et 
al. 2007), further studies are needed. 
Since in the crystal structure of MANF 
the C-terminal amino acids 138-158 were 
not visible (III), further structural analysis 
of the C-terminal domain may give 
additional information about the molecular 
mechanism of MANF and CDNF action. 
5.1.5. CDNF as potent as GDNF in the 
6-OHDA model of PD   
Since MANF was described as a survival 
factor for mDA neurons in vitro (Petrova 
et al. 2003), it was logical to ask whether 
CDNF has similar functions. We tested 
CDNF in a rat 6-OHDA model of PD (I), 
which is commonly used for preclinical 
studies of novel potential therapeutic 
agents. Several growth factors have 
neuroprotective effects in 6-OHDA or 
MPTP toxin models of PD, whereas only 
few molecules promote neurorestoration 
in these models. In vivo neurorestorative 
effects  of  GDNF and NRTN on 
midbrain dopaminergic neurons are well 
documented. However, clinical trials of 
GDNF protein and NRTN gene therapy 
in PD patients have not met expectations 
(see 5.4.). Therefore, novel candidates for 
therapeutic target molecules are needed 
for the treatment of neurodegenerative 
diseases. CDNF may be one of them.  
T h e  n e u r o p r o t e c t i v e  a n d 
neurorestorative activities of CDNF 
in the 6-OHDA rat model of PD were 
comparable to those of GDNF (I). We 
used a partial 6-OHDA lesion model, in 
which striatal 6-OHDA injection leads 
to protracted retrograde degeneration 
of the nigrostriatal pathway. In the 
neurorestorative experiments, 6-OHDA 
was injected into the striatum four weeks 
before a single injection of CDNF. The 
CDNF dose (10 μg) was chosen based 
on our dose-dependence studies, which 
showed that this was the most effective 
dose (I), and the same dose (10 μg) has 
been effective also for GDNF in the same 
model system (Aoi et al. 2000). After one 
week from the striatal 6-OHDA injection 
starts a rapid loss of nigral dopaminergic 
neurons (Sauer and Oertel 1994). This is 
completed within fi ve weeks, and followed 
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by more protracted loss nigral neurons for 
several weeks (Sauer and Oertel 1994). 
At the time of CDNF injection the rapid 
loss of nigral dopaminergic neurons was 
presumably still ongoing. The CDNF 
injection induced recovery of motor 
function, which was signifi cant at 8 weeks 
after injection (I). This suggests that 
CDNF prevented further degeneration 
of dopaminergic neurons and fi bers, and 
maintained or increased the functionality 
of remaining neurons. Whether CDNF 
is able to induce sprouting of striatal 
dopaminergic fi bers or upregulation of TH 
expression as has been reported for GDNF 
(Hoffer et al. 1994; Hudson et al. 1995) is 
not known, and needs further studies. 
Although CDNF and GDNF both 
induced protection and functional 
restoration of nigral dopaminergic 
neurons, they are structurally unrelated 
proteins. GDNF receptor complexes 
and signalling mechanisms are well 
characterized, whereas the target 
molecules i.e. putative receptor(s) and 
signalling pathways activated by CDNF 
are unknown so far. Oxidative stress, 
mitochondrial dysfunction, apoptotic 
cell death and inflammation are related 
to the 6-OHDA toxicity (Schober 2004). 
Apparently CDNF is able to activate 
signalling pathways which counteract 
some of these phenomena. Does CDNF 
affect directly on mDA neurons, or is the 
protective effect mediated by other cell 
types? Does CDNF affect for example 
microglia and astrocytes, and reduce the 
infl ammatory response related to 6-OHDA 
toxicity? Several growth factors which are 
protective in the rat 6-OHDA model of 
PD are also glial mitogens (Table 1), and 
their effect on dopaminergic neurons is 
presumably indirect. Whether this is true 
for CDNF or MANF is unclear. We did 
not detect statistically signifi cant survival 
promoting effect of CDNF or MANF 
on embryonic dopaminergic neurons in 
culture differently from GDNF, which 
significantly promoted the survival and 
TH expression of embryonic dopaminergic 
neurons in vitro (data not shown). This 
suggests that the potential survival 
promoting effect of CDNF on embryonic 
dopaminergic neurons is indirect, and 
the cells mediating the survival were 
not present in sufficient amounts in 
the midbrain cultures. Alternatively, 
embryonic dopaminergic neurons do not 
express the target molecules for CDNF. 
It is currently unclear why we have not 
been able to reproduce the results by 
Petrova et al. (2003) showing the survival 
promoting effects of MANF on embryonic 
dopaminergic neurons in vitro. 
ER stress and UPR are related to 
the 6-OHDA toxicity in vitro, although 
their role in the 6-OHDA toxicity in vivo 
is still unclear (Silva et al. 2005). Could 
extracellularly delivered CDNF inhibit ER 
stress induced by 6-OHDA? Manf mRNA 
expression was upregulated by 6-OHDA 
treatment in mouse dopaminergic MN9D 
cell line (Holtz et al. 2005). Whether 
6-OHDA treatment affects to endogenous 
levels of CDNF or MANF expression 
in rat brain in vivo has not been studied. 
ER stress is also induced by simulated 
ischemia in vitro (Szegezdi et al. 2006a). 
Recombinant MANF protein was able to 
prevent ischemia-induced cell death on 
cardiac myocytes in vitro (Tadimalla et 
al. 2008). Thus, the neurotrophic activity 
of extracellular CDNF (I) or MANF 
(Voutilainen et al. submitted) on adult 
rat dopaminergic neurons may inhibit the 
ER stress-induced cell death related to 
6-OHDA toxicity.  
Since some of the SAPLIPs have 
neurotrophic activities (Bruhn 2005), it 
is possible that the saposin-like domain 
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of CDNF and MANF mediates their 
neurotrophic activities. The saposin-
like domain may bind to cell surface and 
induce survival promoting signalling via 
a transmembrane receptor protein (Fig. 
10D), whereas the C-terminal domain 
with the CXXC motif may mediate 
intracellular cytoprotective activity 
against ER stress (III). It is also possible 
that the neurotrophic and cytoprotective 
(“anti-ER stress”) activities are mediated 
by the same structural motif. Could 
the C-terminal domain mediate the 
neurotrophic activity of CDNF and 
MANF? Could the C-terminal domain of 
the putative cell-surface bound CDNF or 
MANF catalyse reduction or oxidation of 
a disulphide bond on another cell surface 
protein e.g. receptor ectodomain, and 
induce survival promoting signalling in 
the cell? Alternatively, is extracellular 
CDNF or MANF taken up by the cell, 
where it induces cytoprotective effects? 
We have recently shown that CDNF is 
transported from the striatum to the SN in 
vivo, suggesting that CDNF is endocytosed 
(Merja H. Voutilainen and Mart Saarma, 
unpublished results). Future studies will 
give us a better understanding on the 
neurotrophic and cytoprotective activities 
of CDNF and MANF, and whether or how 
they are related.  
5.2. Novel neurotrophic factors for 
midbrain dopaminergic neurons
Neurotrophic factors are, according 
the traditional view, secreted proteins 
provided by the target tissue which 
promote the survival of neurons during 
the developmental period of PCD. 
Although extensively studied, the role 
of neurotrophic factors in the target-
innervation of dopaminergic neurons has 
remained unclear (Andressoo and Saarma 
2008). Potential target-derived factors 
for mDA neurons include GDNF, NRTN, 
BDNF, NT-4 and FGF-2 (Krieglstein 
2004). Are CDNF and MANF target-
derived neurotrophic factors for midbrain 
dopaminergic neurons?   
We have shown that CDNF is a 
secreted protein in vitro that prevents 
the death of adult rat dopaminergic 
neurons in vivo (I). In adult, Cdnf mRNA 
was expressed in the striatum and in 
the midbrain, and CDNF protein was 
detected in the SN, although not in the 
TH-positive dopaminergic neurons (I). 
At P1 and P10, Cdnf mRNA and protein 
was detected in the striatum and SN, 
although at low level (I).  Thus, CDNF is 
present in the nigrostriatal system around 
the two postnatal PCD peaks of midbrain 
dopaminergic neurons at P2 and P14 
(Burke 2004). Gdnf mRNA levels are 
relatively high in the striatum at the time 
of the second peak of PCD as compared 
to the levels in adult (Choi-Lundberg and 
Bohn 1995; Schaar et al. 1993; Strömberg 
et al. 1993). Differently from GDNF, 
our studies do not suggest transient 
postnatal upregulation of striatal CDNF 
expression in the mouse. Consistent with 
the neurotrophic hypothesis, GDNF is 
retrogradely transported via dopaminergic 
neurons from the striatum to SN (Tomac et 
al. 1995b). As already mentioned, CDNF 
is transported from the striatum to the SN; 
however, it is currently unclear whether the 
transport occurs via dopaminergic neurons 
(Merja H. Voutilainen and Mart Saarma, 
unpublished results). These data, although 
not conclusive, indicate that CDNF may 
function as a target-derived neurotrophic 
factor for mDA neurons. However, based 
on the expression analysis (I), it seems 
likely that endogenous CDNF secreted by 
other sources than the striatal target may 
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affect mDA neurons and support their 
survival.   
Manf mRNA and protein were also 
detected in the developing nigrostriatal 
system. MANF was present in the striatum 
and midbrain postnatally at P1 and P10, 
and also in the striatum of adult mouse. 
In embryo, Manf mRNA was expressed in 
the midbrain at embryonic days E13 and 
E18, and MANF protein was detected in 
the midbrain at E16 by IHC (II). Thus, 
also MANF may have a role in the 
development of midbrain dopaminergic 
system. In adult, MANF protein was 
localized in TH-positive dopaminergic 
neurons in the SN (II). Similarly with 
CDNF, MANF promotes the survival 
of adult rat dopaminergic neurons in a 
6-OHDA model of PD (Voutilainen et al. 
submitted). Whether MANF functions 
as a target-derived neurotrophic factor 
for midbrain dopaminergic neurons is 
currently unknown.  
 Neurotrophic factors with survival 
promoting activities on mDA neurons are 
known to affect other neuronal populations 
as well. GDNF supports the survival 
of different neuronal populations in the 
CNS and PNS, including motoneurons 
and enteric, sensory, parasympathetic 
and sympathetic neurons (Airaksinen and 
Saarma 2002). CDNF (I) or MANF (data 
not shown) did not promote the survival 
of embryonic motoneurons or DRG 
neurons, or postnatal SCG neurons in 
vitro. However, this does not exclude the 
possibility that CDNF and MANF affect 
these neurons in vivo, or other neuronal 
types in the CNS or PNS. Thus, additional 
studies are needed, for example using 
in vitro organotypic cultures, or in vivo 
models of neurodegeneration, including 
models of motoneuron degeneration (e.g. 
ALS models), models of Huntington’s 
disease with striatal neurodegeneration, or 
models of AD. 
 
5.3. Roles of CDNF and MANF in non-
neuronal tissues? 
CDNF and MANF are widely expressed 
in the brain and in non-neuronal tissues 
of mouse and human (I, II), suggesting 
that both proteins have important roles 
not only in the neuronal survival but 
also in the survival, proliferation and 
differentiation of non-neuronal cells 
and tissues. Non-neuronal roles are 
common for neurotrophic factors, e.g. 
GDNF regulates kidney development and 
spermatogenesis (Airaksinen and Saarma 
2002), and BDNF has an important role 
in the heart development (Zacchigna et al. 
2008).
In the tissue samples analyzed, high 
levels of Manf mRNA and protein were 
detected in the liver and testis, whereas 
Cdnf mRNA and protein levels were 
relatively high in the skeletal muscle, 
heart and testis (I, II). The skeletal 
muscle, heart and testis are tissues with 
high energy production by mitochondria 
and subsequent oxidative stress. Whether 
CDNF or MANF have a cytoprotective 
role against oxidative stress in these 
tissues is unknown. CDNF and MANF 
are also expressed in secretory organs and 
tissues, including the salivary gland (I, 
II), choroid plexus of brain ventricles (II), 
pancreas (II) and testis (I, II) (Mizobuchi 
et al. 2007), in accordance with the 
putative role of MANF (and CDNF) as 
intracellular chaperones that are needed 
in tissues of high protein synthesis and 
secretion. Whether endogenous CDNF 
and MANF proteins are secreted into body 
fl uids, including the cerebrospinal fl uid, 
serum or saliva has not been studied. 
Discussion
51
Interestingly, it was recently shown 
that MANF may regulate cell proliferation 
in vitro (Apostolou et al. 2008). Inhibiton 
of MANF expression by RNAi increased 
proliferation of HeLa cells, whereas 
overexpression of MANF in U2OS 
osteosarcoma cells inhibited proliferation 
(Apostolou et al. 2008). Whether CDNF 
affects cell proliferation in vitro, or 
whether MANF or CDNF have roles in 
the cell proliferation in vivo, is currently 
unknown. 
5.4. CDNF and MANF as therapeutic 
proteins
Evidence for the potential trophic effects 
of CDNF and MANF is gradually 
accumulating. After the fi rst publication 
of MANF as a survival promoting factor 
for midbrain dopaminergic neurons in 
vitro (Petrova et al. 2003), we showed 
that extracellular CDNF has neurotrophic 
effects on 6-OHDA-lesioned mDA system 
in a rat model of PD (I). Similarly, our 
recent studies showed neuroprotective 
and neurorestorative effects of MANF 
in a 6-OHDA model of PD (Voutilainen 
et al. submitted). An intrastriatal MANF 
(10 μg) injection 6 hours before a striatal 
6-OHDA injection was able to prevent 
the degeneration of nigral dopaminergic 
neurons. Resembling the effects of CDNF 
(I), also MANF (10 μg) induced functional 
recovery of the mDA system when given 
four weeks after the 6-OHDA lesion 
(Voutilainen et al. submitted). Effects of 
recombinant MANF protein have also been 
studied in an experimental model of stroke 
in rats (Airavaara et al. 2009). MANF (6 
μg) admistration into the cerebral cortex 
before MCAO signifi cantly reduced the 
volume of infarction as measured after two 
days, and reduced markers of apoptosis in 
the ischemic cortex. MANF pre-treatment 
also improved motor recovery after stroke, 
although with some delay (Airavaara et al. 
2009). Furthermore, MANF protein added 
to the culture medium of cardiac myocytes 
prevented cell death induced by simulated 
ischemia in vitro (Tadimalla et al. 2008).
CDNF (I) is clearly a potential novel 
protein for the treatment of PD. Several 
growth factors have been reported as 
a survival factors for mDA neurons, 
but only GDNF and NRTN have well-
established neurorestorative effects in 
preclinical models of PD. However, recent 
clinical studies with GDNF (Lang et al. 
2006) and NRTN (Ceregene Inc. press 
release at 26th of November 2008) have 
not been successful; thus, novel potential 
molecules are needed. Protein misfolding 
and aggregation is seen in many 
neurodegenerative diseases, including 
PD, AD and ALS. Since MANF and 
presumably also CDNF has cytoprotective 
role against ER stress in vitro, they may 
have protective effects against several 
neurodegenerative diseases. 
Since neurotrophic factor proteins 
cannot cross the BBB, the method of 
delivery has to be carefully considered 
when designing preclinical trials for NTF 
therapy. In the recent clinical trials, GDNF 
protein was delivered by an intraputamenal 
infusion (Gill et al. 2003; Lang et al. 2006; 
Patel et al. 2005; Slevin et al. 2005), 
whereas neurturin was delivered by a 
gene therapy approach using AAV2 vector 
(Marks et al. 2008). Cell therapy with 
encapsulated or naked NTF-secreting cells 
implanted into the brain is also a potential 
method for NTF therapy (Aebischer and 
Ridet 2001; Lindvall and Wahlberg 2008). 
Recently it was shown that intravenous 
delivery of GDNF plasmid using Trojan 
horse liposomes which bind transferrin 
receptor induced functional recovery 
in a rat 6-OHDA model of PD (Zhang 
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and Pardridge 2009). The expression of 
GDNF transgene was regulated by a TH 
promoter (Zhang and Pardridge 2009). 
Alternative therapeutic strategies could 
include receptor agonists or inhibitors of 
NTF degradation. Whether some of these 
therapeutic strategies are applicaple for 
CDNF and MANF will be revealed in the 
future.  
An important question in NTF 
therapy is the potential side effects. GDNF 
was originally introduced as a specific 
neurotrophic factor for mDA neurons 
(Lin et al. 1993), but the claim is no 
longer valid. Although CDNF and MANF 
have potent effects on adult midbrain 
dopaminergic system (I) (Voutilainen et 
al. submitted), we do not know which 
other CNS or PNS neuronal types or non-
neuronal cells CDNF may affect in vivo. 
Further preclinical studies are needed to 
assess the potency of CDNF and MANF 
as therapeutic agents for PD and other 
neurodegenerative diseases, and their 
possible side effects.
5.5. Receptors for CDNF and MANF 
are unknown 
Molecular mechanism of the neurotrophic 
effect of CDNF (I) and MANF (Petrova 
et al. 2003; Voutilainen et al. submitted) 
on the nigral dopaminergic neurons, and 
the protective effect of MANF against 
stroke (Airavaara et al. 2009) is currently 
unknown. What could be the interacting 
and/or signalling partner(s) of CDNF and 
MANF on the plasma membrane? 
Endocytos is  of  ex t race l lu la r 
prosaposin is mediated by low-density 
lipoprotein receptor-related protein 1 
(LRP1), a multifunctional transmembrane 
cell surface receptor, which is present 
in most cells and is involved in various 
funct ions including  l ipoprotein 
metabolism and activation of lysosomal 
enzymes (Hiesberger et al. 1998). LRP1 
has multiple ligands, including platelet-
derived growth factor (PDGF) and TGFβ, 
and mediates intracellular signalling events 
(Lillis et al. 2008). It has been suggested 
that PSAP and SapC bind to a G-protein 
coupled cell surface receptor (Hiraiwa 
et al. 1997). PSAP also interacts with 
gangliosides which apparently participate 
in the receptor binding and signalling 
(Misasi et al. 1998; Hiraiwa et al. 1997). 
Whether CDNF and MANF bind a 
transmembrane protein receptor which 
subsequently activates intracellular 
signalling cascades, is not known. The 
possible binding of CDNF and MANF to 
LRP1, or the involvement of a G-protein 
coupled receptor in their signalling is 
not known. Would the lipid binding 
of CDNF and MANF be essential for 
subsequent activation of a transmembrane 
receptor protein? Do CDNF and MANF 
interact with glycolipids (gangliosides) 
which mediate their interaction with 
a transmembrane receptor protein and 
subsequent signaling? It is also unknown 
whether secreted CDNF and MANF 
proteins interact with extracellular matrix 
components. Whether CDNF and MANF 
use the same signalling receptors, or not, is 
also unknown. Differing surface residues 
between human CDNF, and human MANF 
and DmMANF proteins were identified 
(III), but their functional relevance remains 
to be studied in the future.    
5.6. Evolutionarily conserved function?
In CDNF and MANF proteins, the 
N-terminal saposin-like domain and the 
C-terminal putative “anti ER-stress” 
domain are combined in a unique way 
(III). In the early evolution a MANF/
CDNF gene has presumably emerged as 
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a combination of an ancestral saposin-
like gene and an “anti-ER stress” gene, 
with putative membrane binding and 
cytoprotective activities, respectively. 
Since this functional combination has 
been an evident success, the invertebrate 
MANF/CDNF gene has duplicated during 
evolution, creating the two paralogs CDNF 
and MANF found in the vertebrates. 
Interestingly, studies with Drosophila 
MANF (DmMANF) deficient flies 
indicate that DmMANF functions as a 
neurotrophic factor in the fly (Palgi et 
al. 2009). The genomic-null flies die in 
early larval stage, and mutant embryos 
show axonal degeneration, cuticular 
defects, and non-apoptotic cell death. 
Importantly, DmMANF is needed for the 
maintenance of dopaminergic neurites and 
dopamine levels (Palgi et al. 2009). Based 
on rescue experiments, human MANF is 
an orthologue of DmMANF (Palgi et al. 
2009). 
Gene ablation studies will presumably 
reveal the roles of CDNF and MANF 
in vivo. Our group has recently created 
CDNF deficient mice, which to our 
surprise (and excitement) die at early 
embryonic stage (Maria Lindahl and Mart 
Saarma, personal communication). This 
clearly shows that CDNF, as DmMANF, 





CDNF and MANF proteins form a novel evolutionarily conserved protein family. 1) 
Paralogous CDNF and MANF are found in the vertebrates, whereas a single CDNF/
MANF ortholog is found in the invertebrates.
Mammalian CDNF and MANF are widely expressed in the brain, including 2) 
midbrain and striatum, as well as in several non-neuronal tissues.
CDNF and MANF are secreted proteins. Protein production and purification 3) 
schemes for recombinant CDNF and MANF proteins have been established. 
Neuroprotective and neurorestorative activity of CDNF protein on adult rat 4) 
midbrain dopaminergic neurons was studied in a partial 6-OHDA lesion model of 
PD. Intrastriatal CDNF protein was neuroprotective, when given before intrastriatal 
6-OHDA. Importantly, CDNF induced functional recovery of nigrostriatal 
dopaminergic system, when given after 6-OHDA lesion. CDNF was as effi cient as 
GDNF in both model systems. CDNF is a potent trophic factor for the treatment of 
PD. 
The crystal structure of human MANF and CDNF was resolved. The structure 5) 
consists of two domains and is consistent with the putative bifunctionality. The 
N-terminal saposin-like domain presumably interacts with membranes and mediates 
neurotrophic activities. The C-terminal domain is presumably unfolded, and contains 
a CXXC motif, which may have disulphide oxidoreductase or isomerase activities. 
Thus, the C-terminal domain may have cytoprotective activities against ER stress. 
This study gave the fi rst insights into the biology and therapeutic potential of the novel 
CDNF/MANF proteins. What are the molecular interactions and signalling pathways 
related to the potential neurotrophic and cytoprotective activities of CDNF and MANF 
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